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Bone health is maintained by a balanced remodelling process that ensures 
the continual replacement of old bone, weakened by microfractures, with new 
bone. This is a coupled process involving bone resorption by osteoclasts and 
new bone formation by osteoblasts (McCormick RK; 2007). The equilibrium 
between bone formation and resorption is important, because an imbalance of 
bone resorption and formation results in several bone diseases. For example, 
excessive resorption by osteoclasts without the corresponding amount of new-
formed bone by osteoblasts contributes to bone loss and osteoporosis 
(Florencio-Silva R, et al., 2015). 
The past decade has witnessed a remarkably increased awareness of 
osteoporosis as a major health problem that is associated with profound socio-
economic consequences (Dunitz M, 2001). Osteoporosis is a systemic skeletal 
disorder and is a result of loss of skeletal mass.  The term “osteoporosis” is 
derived from the Greek language: osteon means bone, and poros is a small 
hole. Thus the term “osteoporosis” is quite descriptive of the changes in bone 
tissue that can be observed in this generalized skeletal disease (Dunitz M, 
1998). In the European Union (EU 27), an estimated 5.5 million men and 22 
million women have osteoporosis.  About 6.6% of men and 22.1% of women 




bone mass, microarchitectural deterioration of bone tissue and an increase in 
bone fragility and susceptibility to fracture (Hammad LF, 2015; Schürer C, et al 
2015).  Osteoporotic fractures are a significant cause of morbidity and mortality 
(Wheater G, 2013). There have been impressive advances in understanding the 
epidemiology and pathogenesis of osteoporosis and its associated fractures, in 
the application of physical and biochemical methods to its diagnosis and 
evaluation, and in the therapeutic approaches to prevention and treatment of 
postmenopausal and other forms of osteoporosis (Dunitz M, 2001). The 
longterm use of drugs such as antiepileptics and antidepressants could affect 
the onset of osteoporosis. 
2. BONE METABOLISM 
Bone is essential for providing skeletal strength and vital organ protection, 
and is a mineral reservoir for calcium and a site for immune-cell development. 
Bone cell homeostasis is maintained by the balanced functions of primarily two 
cell-types: osteoblasts, which build bone, and osteoclasts which resorb bone 
(Walsh MC, et al., 2014).  There exist two types of bone tissue in the adult, 
cortical or compact bone, and spongy or cancellous bone. Most bones have an 
outer cortical casing comprising an outer (periosteal) and inner surface which 
encloses the cancellous bone and marrow space. Bone comprises an organic 




of collagen fibres, which account for 90% of skeletal weight in the adult. Bone is 
constantly being broken down and rebuilt in a process called remodelling. The 
cellular link between bone-resorbing cells – osteoclasts, and bone-forming cells 
– osteoblasts, is known as coupling (Marcus R,et al., 1995; Kanis JA, 1994). 
 
2.1. Bone formation and resorption 
Bone formation takes place in the organism not only during embryonic 
development and growth but throughout life in the processes of normal bone 
remodelling and fracture repair. In the mature adult, skeletal size is neither 
increasing nor decreasing. Despite this, bone is continuously being turned over, 
so that the net activity of bone-resorbing cells equals the net activity of bone-
forming cells. In the adult, this activity is largely accounted for by bone 
remodelling. Bone remodelling is responsible for removal and repair of 
damaged bone to maintain the integrity of the adult skeleton and mineral 
homeostasis. (Kanis JA, 1994; Marcus R, et al 1995; Dunitz M, 2001; Ragatt LJ 
and Partridge NC; 2010). Bone remodelling occurs over several weeks and is 
performed by clusters of bone-resorbing osteoclasts and bone-forming 
osteoblasts arranged within temporary anatomical structures known as “basic 
multicellular units” (BMUs). Traversing and encasing the BMU is a canopy of 




a leading front of osteoclasts and a tail portion comprising osteoblasts. (Ragatt 
LJ and Partridge NC; 2010). 
Osteoblasts are differentiated from osteoprogenitor cells. Osteoblastic 
cells comprise a diverse population of cells that include immature osteoblast 
lineage cells and differentiating and mature matrix-producing osteoblasts 
(Ragatt LJ and Partridge NC; 2010). A mature osteoblast is derived from the 
preosteoblast and expresses all of the differential functions required to 
synthesize bone. The osteoblast is the cell responsible for the synthesis of 
collagen and other bone proteins. It also has an important role in the 
subsequent mineralization of the matrix which leads to the final stage of 
osteoblast differentiation. The most mature or terminally differentiated cells of 
the osteoblast lineage are osteocytes, which not capable of cell division. They 
are trapped within the bone matrix during the process of bone formation, and 
are interconnected to osteoblast and other osteocytes by fine intercellular 
projections running within bone canaliculi (Kanis JA, 1994; Marcus R, 1995). 
They are critical for maintaining fluid flow through the bone, and changes in this 
fluid flow may provide the signal for the cellular response to mechanical forces 
(Raisz 1999). Data have been obtained that support the idea that osteocytes 
initiate and direct the subsequent remodelling process that repairs damaged 
bone (Ragatt LJ and Partridge NC; 2010). Bone lining cells are usually 
designated as part of the osteoblast lineage and are believed to be derived from 




that are undergoing neither formation nor resorption. They have fewer 
organelles than the active osteoblast, further suggesting that they may be 
largely a selective barrier between bone and other extracellular compartments, 
and contribute to mineral homeostasis by regulating the fluxes of calcium and 
phosphate in and out of bone fluids (Marcus R, 1995; Kanis JA, 1994; Raisz 
LG,1999; Ragatt LJ and Partridge NC; 2010). 
The other major cell type found in bone is the osteoclast. This is a 
multinucleated cell which is responsible for bone resorption. The precursors of 
osteoclasts are hemopoietic mononuclear cells which are resident in the bone 
marrow. The functional role of the osteoclast is to resorb bone, a composite 
matrix consisting of both inorganic and organic elements. The initial step in 
bone resorption is attachment of the cell to the matrix by attaching on to a bone 
surface and secreting acid and lysosomal enzymes into the space provided 
between its apical surface and the mineralized bone surface. The surface of the 
osteoclast at this interface is ruffled by cytoplasmic extensions that infiltrate the 











Figure 1. Bone remodelling. Modified by Weilbaecher KN, et al., 2011.  
  
2.2. Steps of remodelling 
The bone remodelling cycle involves a complex series of sequential steps 
that are highly regulated (Kanis JA, 1994). Bone remodelling can be divided into 
the following six phases, namely, quiescent, activation, resorption, reversal, 





Figure 2. Steps of bone remodelling. Modified by Compston JE, 2001. 
 
The first step of bone remodelling is the focal attraction of osteoclasts to 
the quiescent bone surface and is termed activation. The term refers to the 
event and not to the activity of the osteoclasts themselves. In health, an 
activation occurs every 10 seconds or so, and its frequency will largely 
determine the number of new remodelling sites present on bone tissue. This 
phase is dependent on the effects of local and systemic factors on 
mesenchymal cells of the osteoblast lineage (Kanis JA, 1994; Raisz LG,1999). 
The second phase of remodelling is resorption, during which the 




Thereafter, the multinucleated cells disappear and are replaced by mononuclear 
cells, which remove collagen remmants and prepare the bone surface for 
subsequent osteoblast-mediated bone formation. Over the next 7-10 days a 
layer of cement substance is deposited which is rich in proteoglycans, 
glycoproteins and acid phosphatase but poor in collagen. Once the osteoclasts 
have completed their work of bone removal, there is a reversal phase during 
which mononuclear cells are seen on the bone surface. They may complete the 
resorption process and produce the signals that initiate formation (Kanis JA, 
1994; Raisz LG,1999; Ragatt LJ and Partridge NC, 2010).  
After resorption and the reversal phase follows the process termed 
coupling, which coordinates this transition and directs bone formation precisely 
to sites of bone resorption. Coupling attracts osteoblasts to the eroded surface 
where they synthesize an osteoid matrix. The amount of new bone formed is 
also dependent on the number and activity of the osteoblasts (Kanis JA, 1994; 
Ragatt LJ and Partridge NC, 2010). 
Once osteoclasts have resorbed a cavity of bone, they detach from the 
bone surface and are replaced by cells of the osteoblast lineage which in turn 
initiate bone formation (Kini U end Nandeesh BN, 2012).  Osteoblasts form a 
sheet of cells within the resorption cavity and synthesize layers of osteoid matrix 
which comprise unmineralized bone tissue and other matrix proteins. Matrix 




osteoid has a lamellated arrangement of collagen due to changes in the 
orientation of collagen bundles. In cancellous bone the lamellae are usually 
parallel to the trabeculae (Kanis JA, 1994).  
When an equal quantity of resorbed bone has been replaced, the 
remodelling cycle concludes. The termination signal(s) that inform the 
remodelling machinery to cease work are largely unknown, although a role for 
osteocytes is emerging. Sclerostin expression, loss of which was the trigger to 
initiate osteoblastic bone formation, probably reverts to normal toward the end 
of the remodelling cycle (Ragatt LJ and Partridge NC; 2010). The process of 
mineralization begins 30 days after deposition of the osteoid, ending at 90 days 
in trabecular and at 130 days in cortical bone (Kini U end Nandeesh BN, 2012). 
The mineral phase of bone is mainly calcium, phosphate and carbonate (10:6:1) 
arranged as crystals predominantly in the form of hydroxyapatite. Crystals of 
hydroxyapatite are elongated and hexagonal in shape, conforming closely to the 
orientation of the collagen fibres. They also contain other ions including sodium, 
magnesium and fluoride. The delay between the onset of matrix synthesis and 
the start of mineralization accounts for the appearance of osteoid in normal 
bone, during which maturation of osteoid occurs. The first step in calcification is 
thought to take place in or around small membrane-bound vesicles, rich in bone 
alkaline phosphatase (BALP) (Kanis JA, 1994). Following mineralization, 
mature osteoblasts undergo apoptosis, revert back to a bone-lining phenotype 




osteocytes. The resting bone surface environment is re-established and 
maintained in quiescent phase until the next wave of remodelling is initiated 
(Ragatt LJ and Partridge NC, 2010; Kini U end Nandeesh BN, 2012). 
 
2.3. Regulation of bone remodelling 
The balance between bone resorption and formation is influenced by such 
interrelated factors (Kini U end Nandeesh BN, 2012). The effects of calcium-
regulating hormones on this remodelling cycle subserve the metabolic functions 
of the skeleton. Other systemic hormones control overall skeletal growth. The 
responses to changes in mechanical force and repair of microfractures, as well 
as the maintenance of the remodelling cycle, are determined locally by 
cytokines, prostaglandins, and growth factors. Interactions between systemic 
and local factors are important in the pathogenesis of osteoporosis (Raisz 
LG,1999). 
 Estrogens 
Estrogen plays crucial roles for bone tissue homeostasis (Florencio-Silva R, et 
al., 2015). Its loss in postmenopausal women leads to osteoporosis 
characterized by low bone mass, altered bone microarchitecture, and increased 




estrogen acts on bone tissue are not completely understood (Florencio-Silva R, 
et al., 2015), several studies have shown that estrogen maintains bone 
homeostasis by inhibiting osteoblast and osteocyte apoptosis and preventing 
excessive bone resorption (Kousteni S, et al., 2002; Emerton KB, et al., 2010) . 
It is now recognized that one of the main mechanisms by which estrogen 
deficiency causes bone loss is by stimulating formation, a process induced by 
stimulation of precursor simultaneously by M-CSF, TNF and RANKL (Roggia C, 
et al., 2001). It follows that estrogens interfere with production of RANKL/OPG 
(Macari S, et al., 2015).  
 
 Androgens 
Androgens have an anabolic effect on bone through the stimulation of the 
osteoblast receptors (Kanis JA, 1994). They have direct receptor-mediated 
effects on bone cells and probably effect skeletal metabolism in a manner 
comparable to estrogen. In addition, the anabolic effect of testosterone on 
muscle mass is probably one of the mechanisms responsible for the greater 
skeletal mass in men than woman at maturity. Unlike women, men do not 
undergo a natural menopause, and spermatogenesis in contrast to ovulation 
occurs throughout life, although it may decline with age. The production of 
gonadal steroids is also sustained, but may wane in the very old, causing 




 IGF - I and II ( Insulin-like Growth Factor I and II ) 
These are polypeptides similar to insulin; they are synthesized by the liver and 
by osteoblasts, and found in high concentrations in the osteoid matrix (Dunitz 
M, 2001). They increase the number and of the osteoblasts, stimulating 
collagen synthesis. They circulate linked to IGF-binding proteins (IGFBP), which 
in turn can exercise stimulatory or inhibitory effects on bone. IGF synthesis is 
regulated by local growth factors and hormones; thus growth hormone, 
estrogens, and progesterone increase its production, while the glucocorticoids 
inhibit it. They also mediate in the osteoblast-osteoclast interaction and actively 
participate in bone remodelling. Insulin-like growth factor (IGF I), formerly 
known as somatomedin C, stimulates the replication of bone cells and 
chondrocytes, and increases production of matrix constituents (Kini U end 
Nandeesh BN, 2012).  Both IGF I and IGF II are produced within bone itself, 
and their activity is modulated by specific binding proteins which are also under 
endocrine control. There may be important species differences in the regulation 
by IGFs, with IGF II dominating in human bone, whilst IGF I is the major 
endogenous IGF in rat bone (Dunitz M, 2001).  
 RANK/RANKL/OPG protein system 
The RANKL/RANK/OPG pathway plays key roles in the development of 
osteoclasts and the regulation of the immune system (Nagy V and Penniger JM, 




kappa-B ligand (RANKL), also identified as TNF-related activation-induced 
cytokine (TRANCE); its signalling receptor, receptor activator of NF-κB (RANK); 
and the soluble decoy receptor osteoprotegerin (OPG) (Walsh MC end Choi Y, 
2014). OPG is a member of the tumor necrosis factor receptor (TNFR) 
superfamily, and acts by competing with receptor activator of nuclear factor 
kappa-B (RANK), which is expressed on osteoclasts for specifically binding to 
RANKL. Transgenic mice that overexpress OPG demonstrated an increase in 
bone density, whilst OPG knockout mice exhibit profound osteoporosis. These 
findings show a crucial role for OPG in the maintenance of bone mass, but it 
seems that OPG may neutralize a TNF-related factor that could stimulate 
osteoclast development. This factor was identified as RANKL, which was 
originally called TRANCE (TNF-related activation-induced cytokine) (Maxhimer 
JB et al., 2015; Schoppet M et al., 2002). OPG expression is regulated both 
positively (e.g., TGF-β, IL-1, TNF, estrogen, and Wnt ligands) and negatively 
(e.g., prostaglandin E2 (PGE2) and glucocorticoids) by a wide array of factors, 
most of which are associated with bone homeostasis (Walsh MC end Choi Y, 
2014). RANKL is produced by osteoblastic lineage cells and promotes 
osteoclast activation leading to enhanced bone resorption and bone loss. OPG, 
which is secreted by osteoblastic cells, prevents RANKL interaction and 





 BMP  
The so-called bone morphogenetic proteins (BMPs) are factors present in 
demineralized bone matrix which can induce the formation of new cartilage and 
bone when implanted into various non-skeletal sites in vivo (Dunitz M, 2001). 
BMPs are included in the TGF-β family. They form a group of 15 proteins able 
to achieve the transformation of connective tissue into bone tissue, for which 
they are considered osteoinductive. They stimulate the differentiation of the 
stem cells toward different cell lines (adipose tissue, cartilage, and bone). They 
strongly promote osteoblastic differentiation and are believed to inhibit 
osteoclastogenesis in addition to stimulating osteogenesis (Kini V end 
Nandeesh BN, 2012). They are known to be important in regulating the 
differentiation of skeletal and other tissues, and may eventually be of 
therapeutic use, e.g. to promote repair of fractures and skeletal defects (Dunitz 
M, 2001).  
 Sclerostin 
Sclerostin is a 190-amino acid secreted glycoprotein made predominantly by 
osteocytes, but also by cementocytes and mineralized hypertrophic 
chondrocytes (Shah AD, et al., 2015). Sclerostin is produced by osteocytes and 
inhibits osteoblast differentiation and bone formation via the Wnt signaling 
pathway (Bhattoa HP, et al., 2013). Wnt signaling is crucial to both bone 




osteoblast differentiation, proliferation, function and survival, and hence to 
increased bone mass (Shah AD, et al., 2015). Upregulation of sclerostin is 
associated with decreased osteogenesis and bone mass (Compton JT and Lee 
YF, 2014). 
 
2.3.1. Bone markers 
Biochemical markers of bone metabolism provide dynamic information about 
the turnover of osseous tissue. They can be broadly classified as reflecting 
either bone formation or bone resorption (Kini V end Nandeesh BN, 2012). 
Markers of bone formation are either by-products of active osteoblasts 
expressed during the various phases of their development or osteoblastic 
enzymes. 
 BALP = Bone alkaline phosphatase 
The level of alkaline phosphatase in serum has been used for more than 50 
years to monitor bone metabolism and is still the most frequently used marker. 
Alkaline phosphatase is an ectoenzyme anchored to the cell surface of 
osteoblasts and other cells (Kini V end Nandeesh BN, 2012).   The serum 
concentration of BALP reflects the cellular activity of osteoblasts. Although its 




bone is associated with calcification of the skeleton and bone formation (Dunitz 
M, 2001). 
 P1NP = Type I procollagen N-terminal propeptide 
P1NP has several functional advantages and has been recommended by the 
Bone Marker Standards Working Group; it has low interindividual variability and 
is relatively stable at room temperature (Wheater G, et al., 2013). In bone, 
collagen is synthesised by osteoblasts in the form of pre-procollagen. These 
precursor molecules are characterised by short terminal extension-peptides: the 
amino (N-) terminal propeptide (P1NP) and the carboxy (C-) terminal propeptide 
(P1CP). After secretion into the extracellular space, the globular trimeric 
propeptides are enzymatically cleaved and liberated into the circulation. P1CP 
has a MW of 115 kDa and is stabilised by disulphide bonds. It is cleared by liver 
endothelial cells via the mannose receptor and therefore has a short serum half-
life of 6–8 minutes. P1NP has a MW of only 70 kDa, is rich in proline and 
hydroxyproline, and is eliminated from the circulation by liver endothelial cells 
by the scavenger receptor (Seibel MJ, 2005). The serum concentration of P1NP 
also reflects changes in the synthesis of new collagen, both by osteoblasts in 
bone and by fibroblasts in other connective tissues (Dunitz M, 2001). P1NP is 
cleared by liver endothelial cells via a macrophage receptor species, the 
scavenger receptor, that recognises and endocytoses modified proteins. P1NP 




form by thermal degradation (Wheater G, et al., 2013). 
 
 
Figure 3.  Schematic representation of the structure of the procollagen molecule.  
 
 CTX 
Type I collagen represents more than 90% of the organic matrix of bone. The 
modern markers of bone resorption, including the C– and N–telopeptides and 
pyridinoline cross-links, represent a vast improvement over the older 








Epilepsy is one of the most common neurological disorders of the brain. 
Worldwide, epilepsy affects almost 70 million people. One in every ten people 
will have at least one epileptic seizure during a normal lifespan, and a third of 
these will develop epilepsy (Engel J and Pedley TA, 2008; Zhaoxia LI, et al., 
2014). The disease is often chronic, and lifelong treatment may be required 
(Svalheim S, at al., 2011). Fracture rates are increased in patients with 
epilepsy. Although this increase may in part be secondary to seizure activity, 
the effects of AEDs on bone also contribute (Engel J and Pedley TA, 2008). 
AEDs are widely used and prescribed as standard treatment not only for 
epilepsy, but for a variety of non-epileptic conditions as well, mainly bipolar 
spectrum disorders and chronic pain states (Reimers A, 2014).  
Antiepileptic drugs (AEDs) may alter bone mineral metabolism and may 
compromise bone health, especially in patients who have taken AEDs for a 
longer period (Levy RH, et al., 2002). A number of theories have been proposed 
to explain why AEDs affect bone, but none explains all the reported effects 
(Svalheim S, at al., 2011). Cytochrome P450 enzyme-inducing AEDs are those 
most commonly associated with negative impact on bone, but studies suggest 
such effect also with valproate. Data on bone-specific effects of newer AEDs 




Patients with epilepsy have a 2-6 times greater risk of bone fractures 
compared with the general population (Svalheim S, at al., 2011). Some 
fractures are caused by seizure-related injuries, or they may be associated with 
the osteopenic effect of reduced physical activity in patients with epilepsy. The 
risk of developing osteoporosis should be taken into consideration in the 
selection of an AED. Bone loss can occur slowly and asymptomatically, and it is 
important to manage it pre-emptively and thus help prevent fractures (Svalheim 
S, at al., 2011). It should be borne in mind that AEDs are used not only to treat 
epilepsy but also for other conditions such as headache and neuropathic pain 
(Beniczky SA, et al., 2012). 
A large number of AEDs are available (Reimers A, 2014). The older 
generation of enzyme-inducing AEDs such as phenytoin (PHT), 
phenobarbitone, primidone, and carbamazepine have been frequently 
associated with accelerated bone loss, resulting from hepatic induction of 
cytochrome P450 (CYP450) hydroxylase enzymes causing catabolism of 
vitamin D to inactive metabolites. This would lead to an increase in parathyroid 
hormone levels, required for the body to convert more vitamin D into its active 
forms, and this increase in PTH would then cause an increase in bone turnover, 
with resultant bone loss over time. However, non-enzyme-inducing AEDs such 
as sodium valproate (SVP) are known to be also associated with accelerated 
bone loss and development of secondary osteoporosis, and consequently 




Phabphal K, et al., 2013). Other unique risk factors, including the use of AEDs 
with sedative effect, have been described as playing important roles in 
increasing the risk of fractures in the epileptic population. A deficit of sun 
exposure, excessive alcohol and tobacco use, and poor dietary habits, are also 
considered to be responsible for the increased prevalence of osteoporosis in 
both the male and female epileptic population (Lazzari AA, et al., 2013). 
This thesis focuses on the newer antiepileptic drugs, in which the effect 
on bone metabolism is not fully known.  
Levetiracetam (LEV), (S)-2-(2-Oxopyrrolidin-1-yl)butanamide, an 
analog of piracetam, is a relatively new broad-spectrum AED with a favourable 
tolerability and efficacy profile and a low potential for drug interactions.   LEV is 
used in treating partial, generalized and myoclonic seizures (Nissen-Meyer LS, 
et al., 2007). Pharmacokinetic studies indicate fairly prompt and complete 
absorption and distribution. Elimination is renal. Interaction studies have shown 
no effect on the metabolism of other compounds, nor the converse (Levy RH, et 
al., 2002). Despite the wide therapeutic use of LEV, to our knowledge there has 




strength properties of femoral bones in rats, along with documentation of 
changes in BMD and biochemical markers of bone turnover. This study 
demonstrates a biphasic dose-dependent effect of LEV on biomechanical bone 
strength, which may be related to microstructural changes in bone matrix 
(Nissen-Meyer LS, et al., 2007). 
Lacosamide (LCM) (SPM 927, formerly harkeroside), the R-
enantiomer of 2-acetamido-N-benzyl-3-methoxypropionamide, is a chemical 
compound with anticonvulsant and anti-nociceptive properties. LCM significantly 
reduces seizure frequency in adult patients with uncontrolled partial-onset 
seizures. The proposed primary mode of action includes selective enhancement 
of the slow inactivation of voltage-gated sodium channels (without affecting fast 
inactivation) (Michelhaugh SK, et al., 2015). In November 2007, a new drug 
application was filed with the FDA for use of LCM as adjunctive therapy in the 
treatment of partial-onset seizures in adults with epilepsy.  LCM was approved 
in Europe on September 3, 2008 as adjunctive therapy in the treatment of 
partial-onset seizures, with or without secondary generalization, for patients with 
epilepsy of 16 years or older (Johannessen LC et al 2009, Halford JJ end 
Lapointe M, 2009). Sex hormone deficiency increases the risk of developing 





fructopyranose sulfamate,  is a carbonic anhydrase inhibitor commonly used in 
patients with focal epilepsy (Giannopoulou EZ, et al., 2015). Preliminary 
evidence suggests its efficacy for treating generalized seizures, and that it may 
have a broad spectrum of efficacy similar to that of lamotrigine. TPM has 
especially favourable pharmacokinetic characteristics. It is well absorbed and it 
is eliminated primarily by the kidneys. It has a plasma half-life of approximately 
24 hours. (Levy RH, et al., 2002).  
Lamotrigine  (LTG), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine. 
Clinical trial experience suggests that LTG also has a broad spectrum of 
antiepileptic efficacy. In monotherapy studies enrolling patients with new-onset 
epilepsy of all types, LTG was found to be as effective as carbamazepine or 
phenytoin, and better tolerated. LTG has efficacy also in the treatment of 
absence and myoclonic seizures (Levy RH, et al., 2002). Lamotrigine is 
eliminated almost entirely by glucuronide conjugation (Perucca E, 1999). Its 


















4. MAJOR DEPRESSIVE DISORDER (MDD)  
MDD is a common psychiatric disorder. Numerous studies have found MDD 
to be associated with accelerated bone loss leading to the development of low 
bone mineral density (BMD) or osteoporosis, which is dependent on the 
duration of depression. Interestingly, various increased anti-inflammatory and 
pro-inflammatory cytokines have also been implicated in influencing osteoclastic 
bone resorption resulting in a decreased BMD. An increase in pro-inflammatory 
markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) occurs in 
depressive disorders, resulting in increased bone resorption (Malik P, et al., 
2013).  Low vitamin D levels have also been found in depressive patients, which 
may also contribute to BMD reduction (Eskandari F, et al., 2007). Other 
possible pathways leading to low BMD in depressive patients are excessive 
smoking, secondary alcohol consumption, dietary deficiencies with low body 
mass index (BMI), and long-term treatment with antidepressants (Malik P, et al., 
2013). The mechanism of action of antidepressants in the regulation of bone 
tissue is not fully understood. Recent studies have found that transporters of 
serotonin may play a role in bone metabolism and that medications which affect 
these transporter systems may also affect bone metabolism (Rabenda V, et al., 
2013). 




Q, et al., 2012). The link between depression, antidepressant use, and 
osteoporosis is becoming more widely understood, and there is mounting 
evidence for an effect of depression and antidepressants on fracture rates 
(Rizzoli R, et al., 2012). Selective serotonin reuptake inhibitors (SSRIs) are 
recommended for first-line pharmacological management of depression 
because they are considered safer and better tolerated than other types of 
antidepressants (Wu Q, et al., 2012). Tricyclic antidepressants (TCAs) and 
selective serotonin reuptake inhibitors (SSRIs) are two of the most widely 
prescribed classes of antidepressants. The mechanisms of action of all these 
agents involve some impact on the serotonin system, though the degree of 
inhibition of the serotonin transporter (5-HTT) system may differ between 
classes (Bruyère O end Reginster JY, 2014). Wu et al studied the effect of 
SSRIs and TCAs on the risk of fractures. Meta-analysis has shown a greater 
risk of osteoporotic fracture (72%) for the groups treated with TCA or SSRI than 
for the non-SSRI and non-TCA groups. However, the basic mechanism of the 
relationship between osteoporotic fractures and SSRI remains unclear (Wu Q, 
et al., 2012; Wu Q, et al., 2013).   
Serotonin is well known as a regulator of mood. An increase in synaptic 
availability of serotonin is known to have an antidepressant effect, and is 
involved in all or part of the mechanism of action of some of the most widely 
used antidepressants. However, serotonin also plays an important role centrally 




peripherally in the cardiovascular and gastrointestinal systems. There is 
increasing evidence that serotonin may also be an important regulatory agent in 
bone metabolism, notably bone mass (Rizzoli R, et al., 2012). Serotonin is 
synthesized by two different genes at two different sites and plays antagonistic 
functions on bone mass accrual at these two sites. When produced peripherally, 
serotonin acts as a hormone to inhibit bone formation. In contrast, when 
produced in the brain, serotonin acts as a neurotransmitter to exert a positive 
and dominant effect on bone mass accrual by enhancing bone formation and 
limiting bone resorption (Bruyère O end Reginster JY, 2014). Based on these 
findings, treatment with antidepressants that increase levels of serotonin in the 
synapses, should lead to increments in bone mass (Rizzoli R, et al., 2012).  
Mirtazapine (MIRTA), 2–methyl-1,2,3,4,10,14b- 
hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, is the only representative 
of the noradrenergic and specific serotonergic antidepressant class. It is a novel 
antidepressant which has a unique dual mode of action. Mirtazapine affects 
norepinephrine transmission via blockade of central α2–adrenoceptors and is a 
potent serotonin 5-HT2 and 5-HT3 receptor antagonist, thereby increasing 
serotonergic stimulation via the 5-HT1 receptor. It has no significant affinity for 
dopamine receptors, a low affinity for muscarinic cholinergic receptors and no 






methoxyphenyl)-ethyl]cyclohexanol, is a phenethylamine derivative widely 
prescribed for the treatment of depression, and its mechanism of action is 
based on the inhibition of the reuptake of serotonin and noradrenaline (SNRI). 
Venlafaxine’s efficacy is comparable to that of tricyclic antidepressants; 
however, the SNRI has fewer adverse effects. As such, the use of venlafaxine 
has increased in recent years (Ebrahimi F, et al., 2015). Although its potency at 
the 5-HTT is less than that of other SSRIs, venlafaxine also inhibits the 
norepinephrine transporter; however, it is considered serotonin-selective 
because its potency at the 5-HTT is more than 100 times its potency at the 
norepinephrine transporter (Shea ML, et al., 2013). 
Trazodone (TRA), 2-{3-[4-(3-chlorophenyl)piperazin-1-
yl]propyl}[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one, is a structurally unique bicyclic 
antidepressant effective in the treatment of depressive disorders, and which 
appears to be less toxic than other antidepressant drugs following an acute 




increasing serotonergic stimulation via the 5-HT1 receptor. Prolonged-release 
trazodone is equally effective as some selective serotonin reuptake inhibitors, 














5. AIMS OF THE STUDY  
In our study we set out the following specific aims: 
Specific aims: 
1   a)  To determine the effect of orchidectomy on bone metabolism in 
rats.  
2  a) To determine the effect of selected antiepileptic drugs 
(levetiracetam, lacosamide, topiramate, lamotrigine) on bone metabolism 
in rats.  
b)  To determine the extent of the (negative) effect of the selected 
antiepileptic drugs in comparison to a control group. 
3  a)  To determine the effect of selected antidepressant drugs 
(mirtazapine, venlafaxine, trazodone) on bone metabolism in rats.  
b)  To determine the extent of the (negative) effect of the selected 






6. MATERIAL AND METHOD 
All animals received humane care in accordance with the guidelines set by the 
institutional Animal Use and Care Committee of Charles University, Prague, 
Faculty of Medicine in Hradec Kralove, Czech Republic. The protocols of the 
experiment were approved by the same committee. The experiments used 
eight-week-old male albino Wistar rats (Biotest s.r.o., Konarovice, Czech 
Republic). The animals were hosted in groups of 4 in plastic cages. During the 
experimental period the animals were maintained under controlled conventional 
conditions (12 hours light and 12 hours dark, temperature 22±2oC, air humidity 
30–70 %). Tap water and standard laboratory diet (SLD, VELAS, a.s., Lysa nad 
Labem, Czech Republic) or SLD enriched with drugs were given ad libitum. The 
weights of the rats were monitored once a week. 
 
6.1. Antiepileptics 
 Levetiracetam (Levetiracetam, UCB Pharma) 
 Lacosamide (Lacosamid, UCB Pharma) 
 Lamotrigine (Lamotrigine, Glenmark) 





 Mirtazapine (Mirtazapin Krka, Czech republic) 
 Trazadone (Trazodoni hydrochloridum, Medicom International s.r.o., 
Brno Czech republic) 













6.3.1. 1st Experiment  
 Rats were fed with SLD enriched with the selected drugs during a 12 
week period; n = 8. 
1. CON-ORX: orchidectomised control fed with SLD 
2. LEV-ORX: orchidectomised rat fed with SLD enriched with LEV (101 
mg/25 g of the diet; Levetiracetam, UCB Pharma) 
3. LCM–ORX: orchidectomised rat fed with SLD enriched with LCM (18 
mg/25 g of the diet; Lacosamid, UCB Pharma) 
4.  LTG–ORX: orchidectomised rats fed with SLD enriched with LTG (39 
mg/25 g of the diet; Lamotrigine, Glenmark) 
5. TPM–ORX: orchidectomised rats fed with SLD enriched with TPM (23 







6.3.2. 2nd Experiment 
 Rats were fed with SLD enriched with the selected drugs during a 12 
week period; n = 8. 
1. CON-ORX: orchidectomised control fed with SLD 
2. MIRTA-ORX: orchidectomised rat fed with SLD enriched with 
MIRTA (1,98 mg/25g of the diet; Mirtazapin Krka, Czech republic) 
3. VENLA–ORX: orchidectomised rat fed with SLD enriched with 
VENLA (12 mg/25g of the diet; venlafaxin TEVA RETARD, Teva 
Pharmaceuticals s.r.o, Czech republic)  
4.  TRA–ORX: orchidectomised rats fed with SLD enriched with TRA 
(12 mg/25g of the diet; Trazodoni hydrochloridum, Medicom 







6.4. Analysis  
6.4.1. Bone homogenates 
Bone homogenate was prepared from the tibiae. After animal sacrifice, both 
tibiae were carefully excised; after removal of all the surrounding skin, muscle 
and other soft tissue, they were stored at -80°C until required. The proximal part 
of the bone (0.1 g) was disrupted and homogenized in 1.5 ml of phosphate 
buffer (PBS, PAA Laboratories GmbH, Pasching, Austria) with a MagNA Lyser 
instrument (Roche Applied Science, Germany) at 6500 rpm for 20s, and cooled 
on the MagNA Lyser Cooling Block. This procedure was repeated three times. 
The raw tissue homogenate was centrifuged at 10,000 g at 4°C for 10 min, and 
the resulting supernatant was collected and stored at -80°C. 
Levels of the markers carboxy-terminal cross-linking telopeptide of type I 
collagen (CTX-I), amino-terminal propeptide of procollagen type I (P1NP), bone 
alkaline phosphatase (BALP), osteoprotegerin (OPG), bone morphogenetic 
protein 2 (BMP-2) and sclerostin were determined in this bone homogenate, 
also using the ELISA method. 
Levels of markers of bone turnover were determined using kits from the firm 
Uscn Life Science Inc., Wuhan, China (P1NP, Procollagen I N-Terminal 




Factor 1, pg/mL; CTX-I, Cross Linked C-Telopeptide Of Type I Collagen; pg/mL; 
BALP, bone alkaline Phosphatase, ng/ml; BMP-2, Bone Morphogenetic Protein 
2, pg/mL; sclerostin, ng/mL ).  
 
6.4.2. Analysis of serum levels of drugs 
 Levetiracetam 
Concentrations of levetiracetam in the samples were determined by a 
modified high-performance liquid chromatography method with UV photodiode-
array detection (Lancelin F, et al., 2007). After alkalinization of the sample (0.05 
mL) levetiracetam and internal standard UCB 17025 were extracted into 
dichloromethane. Organic solvent was evaporated and the residue was 
dissolved and injected for HPLC analysis. Compounds were separated on a 
Zorbax SB-C8 column (Agilent Technologies, USA) at flow rate 1.1 mL/min. The 
mobile phase was composed of 10% acetonitrile, 7% methanol and 83% of a 20 
mM phosphate buffer pH 6.7 with 0.1% triethylamine. UV detection was 
performed at a wavelength of 200 nm. 
 Lacosamide 
LCM was assayed by modified high-performance liquid chromatography 




included precipitation of plasma proteins: 200 µl of acetonitrile and 20 µl of zinc 
sulphate solution (10%) were added to 100 µl of plasma samples in 1.5-mL 
polypropylene centrifugation tubes. The tubes were vortexed for 120 seconds 
and centrifuged at 15,000 rpm for 10 minutes. The supernatant (30 µl) was 
injected into the HPLC system. Analysis was performed on a 2695 Waters 
Separations Module equipped with 996 photodiode array detector and Peltier 
column-thermostat Jet-Stream (Thermotechnic Products). Data acquisition and 
processing were provided with Empower Software (Waters). The analytical 
column was Zorbax SB-C8 (Agilent Technologies) – 150 x 4.6 mm, 3.5 µm. The 
analytical precolumn was Symmetry C18 Guard Column – 20 x 3.9 mm, 5 µm 
(Waters). The mobile phase was pumped at flow rate 0.8 ml/min and consisted 
of acetonitrile:formic acid 0.1 % (30:70, v/v). Temperature on the column was 
set at 30oC, and injection volume was 30 µl. LCM concentration was 
determined at a wavelength of 215 nm (Greenaway C, et al., 2010). 
 Topiramate 
Determination of topiramate in the samples was performed using the gas 
chromatography-mass spectrometry method. This method was a modification of 
a bioanalytical method published previously (Malakova J, et al., 2007). The 
procedure included liquid-liquid extraction of 0.05 mL of the alkalinized sample 
with ethyl acetate. Trimethylanilinium hydroxide was used for flash methylation 




of m/z 352 (for the topiramate derivative) and m/z 296 (for the internal standard 
derivative) were recorded for data evaluation. 
 Lamotrigine 
Concentrations of lamotrigine were measured using a modified method of 
high-performance liquid chromatography with UV photodiode-array detection 
(Malakova J, et al., 2007). Liquid-liquid extraction of a 0.05 mL alkalinized 
sample was carried out into ethyl acetate. After evaporation of the organic 
phase, the residue was dissolved in methanol. Lamotrigine and the internal 
standard BW 725C 78 were separated on a Symmetry C18 column (Waters, 
USA) 150 x 4.6 mm I.D., 5 μm particle size and Symmetry C18 Guard Column 
(20x3.9 mm I.D.). The mobile phase at isocratic flow rate of 1 mL/min contained 
acetonitrile (28%) and 6 mM phosphate buffer pH 6.8 (72%). The eluate was 
monitored at a wavelength of 306 nm. 
 Mirtazapine 
Serum levels of mirtazapine were determined using the HPLC-MS system. 
Sample preparation included precipitation of plasma proteins – 500 µl of 40 mM 
zinc sulfate in 66 % methanol was added to a polypropylene tube containing 
500 µl of plasma sample and 50 µl of 2,000 ng/ml reserpine as internal standard 
(IS). Chromatographic separation was performed on a Hypersil GOLD column 




mm ID). Gradient elution using two solvents - 0.05 M formic acid (A) and 
acetonitrile (B) was started with 15 % solvent B that was increased to 65 % over 
3 min and maintained for 2 minutes, and then was column equilibrated at 15% B 
for 2 min (total run time 7 min). The mobile phase flow was set to 0.2 mL/min 
and an aliquot of 10 µL was injected. LTQ XL (Thermo Fisher Scientific Corp.) 
was used as mass spectrometer with linear ion trap operating on electrospray 
ionization (ESI) at positive MS2 voltage 4.5 kV. Excalibur software was used for 
data analysis. For quantification a calibration curve was compiled relative to IS 
(Borges NC, et al., 2012). 
 Venlafaxine 
Serum levels of venlafaxine were determined using the HPLC-MS system. 
Sample preparation included precipitation of plasma proteins – 500 µl of 40 mM 
zinc sulfate in 66 % methanol was added to a polypropylene tube containing 
500 µl of plasma sample and 50 µl of 2,000 ng/ml reserpine as internal standard 
(IS). Chromatographic separation was performed on a Hypersil GOLD column 
(Thermo scientific) 50 x 21 mm / 5 um with analytical precolumn (C18, 4 x 2.0 
mm ID). Gradient elution using two solvents – 0.05 M formic acid (A) and 
acetonitrile (B) was started with 15 % solvent B that was increased to 65 % over 
3 min and maintained for 2 minutes, and then was column equilibrated at 15% B 
for 2 min (total run time 7 min). The mobile phase flow was set to 0.2 mL/min 




was used as mass spectrometer with linear ion trap operating on electrospray 
ionization (ESI) at positive MS2 voltage 4.5 kV. Excalibur software was used for 
data analysis. For quantification a calibration curve was compiled relative to IS 
(Borges NC, et al., 2012). 
 
 Trazodone 
Serum levels of trazodone were determined using the HPLC-MS system. 
Sample preparation included precipitation of plasma proteins – 500 µl of 40 mM 
zinc sulfate in 66 % methanol was added to a polypropylene tube containing 
500 µl of plasma sample and 50 µl of 2,000 ng/ml reserpine as internal standard 
(IS). Chromatographic separation was performed on a Hypersil GOLD column 
(Thermo scientific) 50 x 21 mm / 5 um with analytical precolumn (C18, 4 x 2.0 
mm ID). Gradient elution using two solvents - 0.05 M formic acid (A) and 
acetonitrile (B) was started with 15 % solvent B that was increased to 65 % over 
3 min and maintained for 2 minutes, and then was column equilibrated at 15% B 
for 2 min (total run time 7 min). The mobile phase flow was set to 0.2 mL/min 
and an aliquot of 10 µL was injected. LTQ XL (Thermo Fisher Scientific Corp.) 
was used as mass spectrometer with linear ion trap operating on electrospray 
ionization (ESI) at positive MS2 voltage 4.5 kV. Excalibur software was used for 
data analysis. For quantification a calibration curve was compiled relative to IS 




6.4.3. Dual energy X-ray absorptiometry analysis 
The rat bone mineral density (BMD, g/cm2) was measured by means of 
dual energy X-ray absorptiometry (DEXA) on a Hologic Delphi A device 
(Hologic, MA, USA) at the Osteocentre of the Faculty Hospital Hradec Kralove, 
Czech Republic. The rats were examined thus on the last day of experiment – 
before sacrifice. Before measurements, a tissue calibration scan was performed 
with the Hologic phantom for the small animal. Bone mineral densities of the 
whole body, in the area of the lumbar vertebrae, and in the area of the femur 
were evaluated by computer using the appropriate software program for small 
animals (DEXA; QDR-4500A Elite; Hologic, Waltham, MA, USA). All animals 
were scanned by the same operator. 
 














Figure 5. Evaluation of BMD in three areas of the rat skeleton 
R1 – lumbar columna (L3-L5); R2 – left femur; R3 – right femur 
 
6.4.4. Biomechanical testing procedure 
Mechanical testing of the rat femoral shaft and femoral neck was done 
with a special custom-made electromechanical testing machine (Martin Kosek & 
Pavel Trnecka, Hradec Kralove, Czech Republic). For the three-point bending 
test, the femur was placed on a holding device with the two support points 18 
mm apart. A small stabilizing preload to 10 N was applied in the anteroposterior 




mm/min was generated until maximal load failure, and the breaking strength 
(maximum load, N) was recorded. When the bone was broken, the thickness of 
the cortical part of the bone was measured by means of a sliding micrometer 
(OXFORD 0-25MM 30DEG POINTED MICROMETER, Victoria Works, 
Leicester, Great Britain). The proximal part of the femur was used for 
compression test of the femoral neck. The diaphysis of the bone was embedded 
into a container using a methacrylate resin, and a vertical load was applied to 
the top of the femoral head. A small stabilizing preload to 10 N was applied and 
increased at a constant speed of 6 mm/min until failure of the femoral neck. The 
breaking strength (maximum load, N) was recorded by the measuring unit 
(Digitalanzeiger 9180, Burster praezisiosmesstechnik gmbh & co kg, 







6.5. Statistical analysis 
Statistical analysis was performed using the program NCSS 2007 
(Number Cruncher Statistical System, Kaysville, Utah, USA). The results are of 
measurements made after 12 weeks of the experiment, and are presented as 
the median and the 25th and 75th percentiles. Comparison of the parameters 
under study employed an analysis of variance with post-hoc multiple 
Figure 6. Biomechanical testing of the rat femoral shaft by three-point bending test in the 




comparison by Fisher’s LSD test and Kruskal-Wallis non-parametrical analysis 
of variance with post-hoc multiple comparison by Dunn’s test (with Bonferroni´s 
modifications). Differences were considered significant at p < 0,05. 
7. RESULTS 
7.1. The effect of orchidectomy on rat bone  
Weight and body composition 
The performed orchidectomy caused a decrease in weight and lean body 
mass in ORX in comparison with the SHAM group (Table 1).  
Levels of bone markers 
Bone markers from specimens of the proximal tibia were measured to 
assess the effects of orchidectomy and treatment on bone formation. 
Determination of the levels of bone turnover markers (OPG) revealed their 
decrease in ORX versus SHAM. Levels of sclerostin were significantly 
increased (Table 2). 
Dual Energy X-Ray Absorptiometry 
In ORX, a significant decrease in the BMD of the whole body and also in the 
area of the lumbar vertebrae and both femurs was demonstrated compared with 
SHAM (Table 3). 
Biomechanical Properties 




femurs, and in the maximal breaking load of both femurs and the neck of the 
femur (table 4). 
 
Parameter SHAM ORX P-value 
Final body weight (g) 562 (541–622) 474 (460,25–490)* 0,0018 
Fat (g) 90,5 (79,1 – 98,6)  103,85 (80 – 114,4)  0,2788 
Lean body mass (g) 368,7 (359,85–399,35) 285,4 (278,6–303,3)* 0,0003 
Tab. 1 Levels of bone markers. Data are expressed as median (25 th – 75 th percentiles), n=8; 
*p < 0.05. 
Parameter SHAM ORX p-value 
BALP (ng/ml) 20,09 (17,21 – 20,51) 18,31 (17,04 – 22,30) 0,7539 
P1NP (pg/ml) 217,21 (164,71 – 248,82) 201,92 (182,58 - 235,28) 0,9015 
OPG (pg/ml) 2,23 (2,12 – 2.46) 1,92 (1,56 – 2,08)* 0,0111 
Sclerostin (ng/ml) 0.268 (0.221–0.279) 0,344 (0,288 – 0,381)* 0,0085 
BMP (pg/ml) 25,14 (21,78 – 26,65) 24,88 (22,42 – 27,57) 0,7502 
CTX 68,27 (48,72 – 78,41) 
, 
99,54 (79,09 – 110,30)* 0,0365 
Tab. 2 Levels of bone markers. Data are expressed as median (25 th – 75 th percentiles), n=8; *p < 
0.05.  
BMD (g/cm2) SHAM ORX p-value 
Whole body  0,184 (0,181 – 0,185) 0,164 (0,161 – 0,167)* 0,00001 
Diaphysis right femur 0,199 (0,197 – 0,214) 0,181 (0,167 – 0,184)* 0,00487 
Diaphysis left femur 0,194 (0,191 – 0,206) 0,176 (0,165 – 0,182)* 0,00589 
Lumbar columna (L3-L5) 0,248 (0,234 – 0,251) 0,203 (0,193 – 0,213)* 0,0002 
Tab. 3 Densitometric parameters. Data are expressed as median (25 th – 75 th percentiles), 




Parameter SHAM ORX p-value 
RF length (mm) 39,02 (38,44 – 39,25) 37,31 (36,58 – 37,96)* 0,0027 
LF length (mm)  39 (38,27 – 39,24) 37,22 (36,88 – 37,67)* 0,0007 
RF diameter (mm) 3,79 (3,72 – 3,9) 3,71 (3,58 – 3,88) 0,5028 
LF diameter (mm) 3,77 (3,64 – 3,83) 3,65 (3,5 – 3,69) 0,3120 
Cortical RF thickness 
(mm) 
63 (61 - 65,5) 63 (61,5 – 65) 0,5920 
Cortical LF thickness 
(mm) 
64 (62 – 64) 63,5 (62,75 – 64,25) 1,0000 
Maximal load of the right 
femoral shaft (N) 
217,4 (198 – 225) 183 (179,25 – 191,25)* 0,0299 
Maximal load of the left 
femoral shaft (N) 
227 (224 – 236,5) 199 (191 – 217)* 0,0269 
Maximal load of the right 
femoral neck (N) 
160 (143 – 181,5) 152,43 (136 – 166)* 0,0489 
Maximal load of the left 
femoral neck (N) 
171 (139,5 – 184) 150.5 (130 – 165)* 0,0484 
Tab. 4 Biomechanical and geometric parameters. Data are expressed as median (25 th – 75 th 
percentiles), n = 8; *p < 0.05. 
 
7.2. Antiepileptic drugs 
The effect of levetiracetam on rat bone metabolism 
Serum concentrations of drugs 
The level of levetiracetam in the LEV-ORX group at the end of the 
experiment was 201,62 (191,9025 - 217,815) µmol/l, equivalent to therapeutic 




Weight and body composition 
The weight of the experimental group decreased, but it is statistically 
insignificant versus the control group. DEXA revealed that the experimental 
group showed significantly decreased fat mass versus the control group (g). 
There were no significant differences in lean body mass between the 
experimental group and the control group (Table 5).  
Levels of bone markers 
As shown in Table 6, levetiracetam administration for 12 weeks caused a 
significant decrease in OPG and a borderline-significant increase in CTX-I. 
PINP and BALP were also increased but without statistical significance. 
Dual Energy X-Ray Absorptiometry 
Using densitometric measurements, we found loss of bone mineral 
density and bone mineral content of the right and left femur compared with 
control groups. There was no statistically significant difference in whole-body 
BMD between the study groups (Table 7). 
Biomechanical Properties 
The measured biomechanical and geometric parameters are shown in 
Table 8. There was no statistically significant difference in these parameters 
between rats receiving levetiracetam and control rats. 
 
Parameter LEV–ORX CON-ORX P-value 
Final body weight 
(g) 
486,5 (472,75 - 490,5) 523 (489 – 543) 0,063 
Fat (g) 71,35 (63,825 - 78,275) 90,3 (83,1 – 127,2)* 0,0087 
Lean body mass (g) 335,4 (330,8 - 349,05) 326,2 (310,9 – 378,8) 0,9864 
Tab. 5 Body weight and fat mass. Data are expressed as median (25 th – 75 th percentiles), 




Parameter LEV–ORX CON-ORX p-value 
BALP (ng/ml) 1,490 (1,198 - 1,694) 1,161(0,794 - 1,382) 0,1806 
P1NP (pg/ml) 87,395 (78,751 - 97,267) 78,977 (73,367 - 81,067) 0,1979 
OPG (pg/ml) 49,628 (48,917 - 51,040) 54,671 (51,932 - 57,835)* 0,0186 
IGF – I (pg/ml) 1,158 (1,117 - 1,192) 1,107 (1,081 - 1,167) 0,8158 
BMP (pg/ml) 831,553 (704,383 - 1005,833) 846,841(633,905 - 985,989) 0,9467 
CTX – I (pg/ml) 2,473 (1,365 - 3,149) 0,972 (0,802 - 1,537) 0,0661 
Tab. 6 Levels of bone markers. Data are expressed as median (25 th – 75 th percentiles), n=8; 
*p < 0.05. 
BMD (g/cm2) LEV–ORX CON-ORX p-value 
Whole body  0,176 (0,174 - 0,176) 0,175 (0,172 - 0,176) 0,5151 
Diaphysis right femur 0,187 (0,177 – 0,1917) 0,195 (0,189 - 0,206) 0,1048  
Diaphysis left femur 0,177 (0,173 – 0,189) 0,195 (0,194 – 0,199)* 0,0181 
Lumbar columna (L3-L5) 0,212 (0,210 - 0,213) 0,207 (0,202 - 0,213) 0,3520 
Tab. 7 Densitometric parameters. Data are expressed as median (25 th – 75 th percentiles), n = 










Parameter LEV–ORX CON-ORX p-value 
RF length (mm) 37,13 (36,89 - 37,62) 37,4 (36,8 - 37,69) 0,9506 
LF length (mm)  37,02 (36,845 - 37,075) 37,45 (36,72 - 37,955) 0,6601 
RF diameter (mm) 3,69 (3,525 - 3,75) 3,63 (3,545 - 3,72)
  
0,7519 
LF diameter (mm) 3,65 (3,335 - 3,72)
  
3,63 (3,515 - 3,945) 0,2092 
Cortical RF thickness 
(mm) 
0,7 (0,678 - 0,728)
  
0,705 (0,673 - 0,728) 0,5283 
Cortical LF thickness 
(mm) 
0,69 (0,658 - 0,74) 0,72 (0,673 - 0,735) 0,6069 
Maximal load of the right 
femoral shaft (N) 
207 (203,5 - 223,25) 216 (203,75 - 227,5) 0,5283 
Maximal load of the left 
femoral shaft (N) 
208 (195,25 - 223,5) 214,5 (196,75-233,75) 0,6332 
Maximal load of the right 
femoral neck (N) 
163,5 (151,75 - 171,25) 156 (136,5 - 171,25) 0,6546 
Maximal load of the left 
femoral neck (N) 
140,5 (134,25 - 148,25) 144 (135,5 – 152) 0,8945 
Biomechanical and geometric parameters. Data are expressed as median (25 th – 75 th 
percentiles), n = 8; *p < 0.05. 
 
The effect of lacosamide on rat bone metabolism 
Serum concentrations of drugs 
The level of lacosamide in LCM-ORX group at the end of the experiment was 
13.49 µmol/L (12.96 - 14.59), considerably below therapeutic levels of the drug 
40 – 80 µmol/L 
Weight and body composition 
Comparison of body composition showed a significantly lower fat mass 




was 18.3 % (100*(1-fatLCM/fatCON) between the groups - for details see 
Tab.9. 
 
Levels of bone markers 
Among the tested bone markers aminoterminal propeptide of procollagen type I 
was significantly lower in the LCM-ORX group. Particular values and a detailed 
list of the other followed parameters are displayed in Tab. 10. 
Dual Energy X-Ray Absorptiometry 
The mineral density of bone evaluated in the whole body and in the area of the 
lumbar vertebrae did not show any significant differences between the groups; 
however in the area of the left as well as the right femur we found significantly 
lower density in the LCM-ORX group compared to the control group (table 11).  
Biomechanical Properties 
The Mann-Whitney U test also showed that medians of biomechanical and 
geometric parameters of right and left femurs did not differ (Table 12).  
 
Parameter LCM-ORX CON-ORX p-value 
Weight (g) 486 (471 – 499) 523 (489 – 543) 0,189 
Fat (g) 73.8 (65,1 – 85,2) 90,3 (83,1 – 127,2)* 0,024 
Lean body mass (g) 340,9 (326,9 – 350,9) 326,2 (310,9 – 378,8) 0,495 







Parameter LCM–ORX CON-ORX p-value 
BALP (ng/ml) 1,490 (1,198 - 1,694) 1,161(0,794 - 1,382) 0,495 
P1NP (pg/ml) 49,4 (34,5 – 67,6) 78,977 (73,367 - 81,067)* 0,005 
OPG (pg/ml) 57,9 (51,1 – 54,5) 54,671 (51,932 - 57,835) 0,372 
IGF – I (pg/ml) 1,17 (1,05 – 1,29) 1,107 (1,081 - 1,167) 0,564 
BMP (pg/ml) 824 (763 – 1055) 846,841(633,905 - 985,989) 0,958 
CTX – I (pg/ml) 0,90 (0,64 – 1,63) 0,972 (0,802 - 1,537) 0,772 
Tab. 10 Levels of bone markers. Data are expressed as median (25 th – 75 th percentiles), n=8; 
*p < 0.05. 
 
BMD (g/cm2) LCM–ORX CON-ORX p-value 
Whole body  0,175 (0,171 - 0,176) 0,175 (0,172 - 0,176) 0,066 
Diaphysis right femur 0,175 (0,160 – 0,179) 0,195 (0,189 - 0,206)* 0,001  
Diaphysis left femur 0,179 (0,169 – 0,185) 0,195 (0,194 – 0,199)* 0,004 
Lumbar columna (L3-L5) 0,212 (0,207 - 0,223) 0,207 (0,202 - 0,213) 0,793 
Tab. 11 Densitometric parameters. Data are expressed as median (25 th – 75 th percentiles), n 









Parameter LCM-ORX CON-ORX p-value 
RF length (mm) 37,4 (37,2 – 37,8) 37,4 (36,8 - 37,69) 0,958 
LF length (mm)  37.3 (36,9 – 38,6) 37,45 (36,72 - 37,955) 0,495 
RF diameter (mm) 3,65 (3,47 – 3,95) 3,63 (3,545 - 3,72)  0,753 
LF diameter (mm) 3,64 (3,62 – 3,67) 3,63 (3,515 - 3,945) 0,958 
Cortical RF thickness 
(mm) 
0,695 (0,680 – 0,740) 0,705 (0,673 - 0,728) 0,958 
Cortical LF thickness 
(mm) 
0,705 (0,695 – 0,750) 0,72 (0,673 - 0,735) 0,263 
Maximal load of the right 
femoral shaft (N) 
224 (204 – 235) 216 (203,75 - 227,5) 0,564 
Maximal load of the left 
femoral shaft (N) 
218 (207 – 229) 214,5 (196,75-233,75) 1,000 
 
Maximal load of the right 
femoral neck (N) 
160 (138 – 178) 156 (136,5 - 171,25) 0,355 
Maximal load of the left 
femoral neck (N) 
146 (128 – 163) 144 (135,5 – 152) 0,897 
Tab. 12 Biomechanical and geometric parameters. Data are expressed as median (25 th – 75 th 
percentiles), n = 8; *p < 0.05. 
 
The effect of lamotrigine on rat bone metabolism 
Serum concentrations of drugs 
The level of lamotrigine in the LTG-ORX group at the end of the 








Weight and body composition 
The weight of the experimental group decreased in a statistically 
significant manner. There was also a significant decrease in fat mass and lean 
body mass compared with the control group (Table 13).  
Levels of bone markers 
As shown in table 14, there were no statistical changes in the levels of 
bone markers. Only the levels of BALP were decreased in the LTG-ORX group 
compared control group, but not statistically significant. 
Dual Energy X-Ray Absorptiometry 
Using densitometric measurements, we found loss of bone mineral 
density of the whole body, right and left femur compared with the control groups 
(Table 15). 
Biomechanical Properties 
Testing of the mechanical strength of the bone tissue by means of three-
point bending revealed a statistically significant decrease in maximal load 
values versus the control group (Table 16). 
 
 
Parameter LTG-ORX CON-ORX p-value 
Weight (g) 415,5 (402,25 – 449,25) 523 (489 – 543)* 0,0014 
Fat (g) 64,4 (59,9 – 70,775) 90,3 (83,1 – 127,2)* 0,0026 
Lean body mass (g) 295,15 (281,85 – 310,8) 326,2 (310,9 – 378,8)* 0,0432 
Tab. 13 Body weight and fat mass. Data are expressed as median (25 th – 75 th percentiles), 





Parameter LTG-ORX CON-ORX p-value 
BALP (ng/ml) 0,868 (0,838 - 0,963) 1,161(0,794 - 1,382) 0,1214 
P1NP (pg/ml) 86,84 (80,244 – 97,172) 78,977 (73,367 - 81,067) 0,1444 
OPG (pg/ml) 52,224 (51,102 – 54,545) 54,671 (51,932 - 57,835) 0,4309 
IGF – I (pg/ml) 1,269 (1,243 – 1,295) 1,107 (1,081 - 1,167) 0,0734 
BMP (pg/ml) 817,627 (774,578 – 890,548) 846,841(633,905 - 985,989) 0,7541 
CTX – I (pg/ml) 0,568 (0,53 – 0,675) 0,972 (0,802 - 1,537) 0,1288 
Tab. 14 Levels of bone markers. Data are expressed as median (25 th – 75 th percentiles), n=8; 
*p < 0.05. 
 
BMD (g/cm2) LTG-ORX CON-ORX p-value 
Whole body  0,168 (0,160 - 0,172) 0,175 (0,172 - 0,176)* 0,0026 
Diaphysis right femur 0,169 (0,163 – 0,177) 0,198 (0,188 - 0,211) 0,1033  
Diaphysis left femur 0,174 (0,1666 – 0,179) 0,197 (0,192 – 0,199)* 0,0039 
Lumbar columna (L3-L5) 0,207 (0,201 - 0,210) 0,214 (0,210 - 0,223) 0,6899 
Tab. 15 Densitometric parameters. Data are expressed as median (25 th – 75 th percentiles), n 









Parameter LTG-ORX CON-ORX p-value 
RF length (mm) 37,05 (36,485 – 37,56) 37,4 (36,8 - 37,69) 0,5660 
LF length (mm)  36,78 (36,12 - 37,11) 37,45 (36,72 - 37,955) 0,2492 
RF diameter (mm) 3,5 (3,435 – 3,565) 3,63 (3,545 - 3,72)  0,0502 
LF diameter (mm) 3,51 (3,47 – 3,54) 3,63 (3,515 - 3,945) 0,2827 
Cortical RF thickness (mm) 0,69 (0,65 – 0,713) 0,705 (0,673 - 0,728) 0,4700 
Cortical LF thickness (mm) 0,67 (0,66 – 0,68) 0,72 (0,673 - 0,735) 0,2099 
Maximal load of the RF 
femoral shaft (N) 
186 (166,75 – 192) 216 (203,75 - 227,5)* 0,0014 
Maximal load of the LF 
femoral shaft (N) 
180 (169,75 – 198) 214,5 (196,75-233,75)* 0,0103 
Maximal load of the right 
femoral neck (N) 
119 (110 -123) 156 (136,5 - 171,25)* 0,0003 
Maximal load of the left 
femoral neck (N) 
117 (109 -120) 144 (135,5 – 152)* 0,0013 
Tab. 16 Biomechanical and geometric parameters. Data are expressed as median (25 th – 75 th 
percentiles), n = 8; *p < 0.05. 
 
The effect of topiramate on rat bone metabolism 
Serum concentrations of drugs 
The level of topiramate in the TPM-ORX group at the end of the experiment was 







Weight and body composition 
The weight of the experimental group decreased in a statistically 
significant manner. There was also a significant decrease in fat mass compared 
with the control group (Table 17).  
Levels of bone markers 
No statistically significant difference in bone turnover markers was found (Table 
18). 
Dual Energy X-Ray Absorptiometry 
A significant loss of BMD was found for the whole body and the right and left 
femurs for both experimental groups compared with the control group (table 19). 
Biomechanical Properties 
The Mann-Whitney U test also showed that medians of biomechanical and 
geometric parameters of right and left femurs did not differ (Table 20). 
 
Parameter TPM-ORX CON-ORX p-value 
Final body weight (g) 486 (474,75 – 493) 523 (489 – 543) 0,0495 
Fat (g) 73,6 (67 – 83) 90,3 (83,1 – 127,2)* 0,0202 
Lean body mass (g) 334 (321,25 – 344,35) 326,2 (310,9 – 378,8) 0,8525 
Tab. 17 Body weight and fat mass. Data are expressed as median (25 th – 75 th percentiles), 






Parameter TPM-ORX CON-ORX p-value 
BALP (ng/ml) 1,528 (1,378 - 1,664) 1,161(0,794 - 1,382) 0,1046 
P1NP (pg/ml) 87,401 (77,619 – 94,04) 78,977 (73,367 - 81,067) 0,1540 
OPG (pg/ml) 52,613 (50,628 – 53,656) 54,671 (51,932 - 57,835) 0,4001 
IGF – I (pg/ml) 1,111 (1,092 – 1,197) 1,107 (1,081 - 1,167) 0,0733 
BMP (pg/ml) 834,857 (707,31 – 1057,472) 846,841(633,91 - 986) 0,9753 
CTX – I (pg/ml) 0,505 (0,478 – 0,652) 0,972 (0,802 - 1,537) 0,0933 
Tab. 18 Levels of bone markers. Data are expressed as median (25 th – 75 th percentiles), n=8; 
*p < 0.05. 
 
BMD (g/cm2) TPM-ORX CON-ORX p-value 
Whole body  0,168 (0,166 – 0,169) 0,175 (0,172 - 0,176)* 0,0406 
Diaphysis right femur 0,179 (0,176 – 0,188) 0,195 (0,189 - 0,206)* 0,0053 
Diaphysis left femur 0,179 (0,173 – 0,190) 
) 
0,195 (0,194 – 0,199)* 0,0136 
Lumbar columna (L3-L5) 0,196 (0,191 – 0,207)
  
0,207 (0,202 - 0,213) 0,3934 
Tab. 19 Densitometric parameters. Data are expressed as median (25 th – 75 th percentiles), n 









Parameter TPM-ORX CON-ORX p-value 
RF length (mm) 37,26 (37,22 – 37,37) 37,4 (36,8 - 37,69) 0,9778 
LF length (mm)  37,3 (37,22 – 37,41) 37,45 (36,72 - 37,955) 0,9017 
RF diameter (mm) 3,52 (3,48 – 3,62) 3,63 (3,545 - 3,72)
  
0,1544 
LF diameter (mm) 3,57 (3,5 – 3,64) 3,63 (3,515 - 3,945) 0,1010 
Cortical RF thickness 
(mm) 
0,74 (0,698 – 0,753) 0,705 (0,673 - 0,728) 0,3400 
Cortical LF thickness 
(mm) 
0,75 (0,693 – 0,75) 0,72 (0,673 - 0,735) 0,5346 
Maximal load of the right 
femoral shaft (N) 
194,5 (188,75 – 201,5) 216 (203,75 - 227,5) 0,0839 
Maximal load of the left 
femoral shaft (N) 
197,5 (192 – 207,75) 214,5 (196,75-233,75) 0,1261 
Maximal load of the right 
femoral neck (N) 
134,5 (126,5 – 149,75) 156 (136,5 - 171,25) 0,1804 
Maximal load of the left 
femoral neck (N) 
139 (121,5 – 153,5) 144 (135,5 – 152) 0,4415 
Tab. 20 Biomechanical and geometric parameters. Data are expressed as median (25 th – 75 th 









Parametr LEV-ORX LCM-ORX TPM-ORX LTG-ORX CON-ORX 
P1NP (pg/ml) 87,40 (78,75 - 97,267) 49,4 (34,5 – 67,6) 87,40 (77,62 – 94,04) 86,84 (80,24 – 97,17) 78,98 (73,37 - 81,07) 
BALP (ng/ml) 1,49 (1,20 - 1,69)* 1,49 (1,20 - 1,69) 1,528 (1,378 - 1,664) 0,868 (0,838 - 0,963) 1,161(0,794 - 1,382) 
OPG (pg/ml) 49,63 (48,92 - 51,04) 57,9 (51,1 – 54,5)** 52,61 (50,63 – 53,66) 52,22 (51,10 – 54,55) 54,67 (51,93 - 57,84) 
CTX (pg/ml) 2,47 (1,37 - 3,15) 0,90 (0,64 – 1,63) 0,505 (0,478 – 0,652) 0,568 (0,53 – 0,675) 0,972 (0,802 - 1,537) 
BMD whole body (g/cm2) 0,176 (0,174 - 0,176) 0,175 (0,171 – 0,176) 
170, 
 
0.168 (0.166 – 0.169) 0,168 (0,16 – 0,172)* 0,175 (0,172 - 0,176) 
BMD RF (g/cm2) 0,187 (0,177 – 0,1917) 0,175 (0,160 – 0,179)*** 0.179 (0.176 – 0.188)* 0,169 (0,163 – 0,177)*** 0,195 (0,189 - 0,206) 
BMD LF (g/cm2) 0,177 (0,173 – 0,189) 0,179 (0,169 – 0,185)*** 0.179 (0.173 – 0.190)* 0,174 (0,167 – 0,179)*** 0,195 (0,194 – 0,199) 
Maximal load of the right femoral shaft 
(N) 
207 (204 - 223) 224 (204 – 235) 195 (189 – 202) 186 (167 – 192)** 216 (204 - 228) 
Maximal load of the left femoral shaft (N) 208 (195 - 224) 218 (207 – 229) 198 (192 – 208) 180 (170 – 198)* 215 (197 - 234) 
Maximal load of the right femoral neck 
(N) 
164 (152 - 171) 160 (138 – 178) 135 (127 – 150) 119 (110 -123)** 156 (137 - 171) 
Maximal load of the left femoral neck (N) 141 (134 - 148) 146 (128 – 163) 139 (122 – 154) 117 (109 -120)* 144 (136 – 152) 




7.3. Antidepressant drugs 
The effect of mirtazapine on rat bone metabolism 
Serum concentrations of drugs 
The level of mirtazapine in the MIRTA-ORX group at the end of the 
experiment was 0,060 mg/L (0,045–0,060 mg/L), equivalent to therapeutic 
levels of the drug 0,030 – 0,080 mg/L. 
 
Weight and body composition 
The weight of the experimental MIRTA-ORX group decreased, but this 
was statistically non-significant versus the control group. DXA revealed that the 
experimental group showed an increase in fat mass versus the control group. 
There were no significant differences in lean body mass between the 
experimental and the control group (Table 22).  
Levels of bone markers 
In the ORX control group, the levels of OPG, BALP, P1NP and BMP-2 
were decreased versus the MIRTA-ORX group, but those of P1NP and BMP-2 
not significantly so. The results from ELISA are shown in Table 23.  
Dual Energy X-Ray Absorptiometry 
In the MIRTA-ORX group there was a significant decrease in BMD of the 
whole body and both femurs, but the BMD of the lumbar vertebrae was 








After mirtazapine administration there was a statistically significant 
decrease in length, and a decrease in thickness (not statistically significant) of 
the cortical bone as compared with the ORX group. There was a statistically 
significant decrease in maximal load of the femoral neck, but the maximal load 
of the femoral shaft was unchanged versus the ORX group (Table 25). 
 
Parameter MIRTA-ORX CON-ORX p-value 
Final body weight (g) 452 (431,25 – 486,25 474 (460,25 – 490) 0,2337 
Fat (g) 99,75 (92,111,03) 103,85 (80 – 114,4) 0,7265 
Lean body mass (g) 265,95 (261,48–289,78) 285,4 (278,6 – 303,3) 0,2827 
Tab. 22 Body weight and fat mass. Data are expressed as median (25 th – 75 th percentiles), 
n=8; *p < 0.05. 
 
 
Parameter MIRTA-ORX CON-ORX p-value 
BALP (ng/ml) 18,31 (17,04 - 22,30) 20,09 (17,21 – 20,51) 0,7539 
P1NP (pg/ml) 201,92 (182,58 – 235,28) 217,21 (164,71 - 248,82) 0,9015 
OPG (pg/ml) 1,44 (1,32 – 1,55) 1,92 (1,56 – 2,08)* 0,0181 
Sclerostin (ng/ml) 0,344 (0,288 – 0,381) 0,268 (0,221 – 0,279)* 0,0085 
BMP (pg/ml) 24,88 (22,42 – 27,57) 25,14(21,78 – 26,65) 0,7502 
CTX-I (pg/ml) 58,79 (55,62 – 60,64) 68,27 (48,72 - 78,41) 0,2637 
Tab. 23 Levels of bone markers. Data are expressed as median (25 th – 75 th percentiles), n=8; 




BMD (g/cm2) MIRTA-ORX CON-ORX p-value 
Whole body  0.159 (0.158–0.166) 0,164 (0,161 - 0,167) 0.9872 
Diaphysis right femur 0.171 (0.159–0.175) 0,181 (0,167 - 0,184)* 0.0394 
Diaphysis left femur 0.161 (0.158–0.168) 0,176 (0,164 – 0,182) 0.0637 
Lumbar columna (L3-L5) 0.200 (0.195–0.208) 0,203 (0,193 - 0,213) 0.8130 
Tab. 24 Densitometric parameters. Data are expressed as median (25 th – 75 th percentiles), n 
= 8; *p < 0.05. 
 
Parameter MIRTA-ORX CON-ORX p-value 
RF length (mm) 36,44 (35,43 – 37,26) 37,31 (36,58 – 37,96)* 0,0211 
LF length (mm)  36,08 (35,29 – 36,72) 37,22 (36,88 – 37,67)* 0,0218 
RF diameter (mm) 3,65 (3,52 – 3,82) 3,71 (3,58 – 3,88) 0,4056 
LF diameter (mm) 3,51 (3,37 – 3,67) 3,65 (3,5 – 3,69) 0,1989 
Cortical RF thickness 
(mm) 
60,5 (58,75 - 62) 63 (61,5 - 65) 0,0912 
Cortical LF thickness 
(mm) 
61,5 (58,5 – 63,25) 63,25 (62,75 – 64,25) 0,6601 
Maximal load of the right 
femoral shaft (N) 
196 (188 – 203,5) 183 (179,25 – 191,25) 0,1391 
Maximal load of the left 
femoral shaft (N) 
201,5 (184,5 – 220,5) 199 (191 – 217) 0,8903 
Maximal load of the right 
femoral neck (N) 
132 (123,7 – 137,5) 152,43 (136 – 166)* 0,0486 
Maximal load of the left 
femoral neck (N) 
133 (126,5 – 146,5) 150,5 (130 – 165)* 0,0494 
Tab. 25 Biomechanical and geometric parameters. Data are expressed as median (25 th – 75 th 





The effect of venlafaxine on rat bone metabolism 
Serum concentrations of drugs 
The level of venlafaxine in the VEN-ORX group at the end of the 
experiment was 0,46 mg/L  (0,3 – 0,625 mg/L), equivalent to therapeutic levels 
of the drug 0,2 – 0,75 mg/L. 
Weight and body composition 
DXA revealed that the experimental group showed a decrease in fat 
mass versus the control group. There were no significant differences in lean 
body mass between the experimental group and the control group (Table 26).  
Levels of bone markers 
The levels of BALP were decreased, while the levels of CTX-I and 
sclerostin were increased. The results from the ELISA determination are shown 
in Table 27.  
Dual Energy X-Ray Absorptiometry 
In the group VENLA-ORX there was a significant decrease in the BMD 
and BMC of both femurs. The results are shown in Table 28.  
Biomechanical Properties 
There were no significant differences in biomechanical testing 
measurement between the experimental group and the control group. The 






Parameter VENLA-ORX CON-ORX p-value 
Final body weight (g) 434,5 (428 – 447) 474 (460,25 – 490)* 0,0415 
Fat (g) 78,7 (70,65 - 85,4) 103,85 (80 – 114,4)* 0,0217 
Lean body mass (g) 294,1 (288,9 – 309,8) 285,4 (278,6 – 303,3) 0,6601 
Tab. 26 Body weight and fat mass. Data are expressed as median (25 th – 75 th percentiles), 
n=8; *p < 0.05. 
 
Parameter VENLA-ORX CON-ORX p-value 
BALP (ng/ml) 7,15 (5,60 – 8,87) 20,09 (17,21 – 20,51)* 0,0000 
P1NP (pg/ml) 210,21 (175,53 – 261,09) 217,21 (164,71 - 248,82) 0,7392 
OPG (pg/ml) 1,64 (1,53 – 1,85) 1,92 (1,56 – 2,08) 0,3184 
Sclerostin (ng/ml) 0,457 (0,405 – 0,484) 0,268 (0,221 – 0,279)* 0,0000 
BMP (pg/ml) 22,22 (19,89 – 23,78) 25,14(21,78 – 26,65) 0,270 
CTX-I (pg/ml) 99,54 (79,09 – 110,30) 68,27 (48,72 - 78,41)* 0,0085 
Tab. 27 Levels of bone markers. Data are expressed as median (25 th – 75 th percentiles), n=8; 










BMD (g/cm2) VENLA-ORX CON-ORX p-value 
Whole body  0,158 (0156 – 0,165) 0,164 (0,161 - 0,167) 0,2688 
Diaphysis right femur 0,161 (0,158 – 0,166) 0,181 (0,167 - 0,184)* 0,010 
Diaphysis left femur 0,154 (0,151 – 0,157) 0,176 (0,164 – 0,182)* 0,0037 
Lumbar columna (L3-L5) 0,202 (0,198 – 0,211) 0,203 (0,193 - 0,213) 0,8904 
Tab. 28 Densitometric parameters. Data are expressed as median (25 th – 75 th percentiles), n 
=8 
 
Parameter VENLA-ORX CON-ORX p-value 
RF length (mm) 37,08 (36,85 – 37,61) 37,31 (36,58 – 37,96) 0,5766 
LF length (mm)  37,24 (36,88 – 37,83) 37,22 (36,88 – 37,67) 0,9236 
RF diameter (mm) 3,54 (3,50 – 3,62) 3,71 (3,58 – 3,88) 0,1083 
LF diameter (mm) 3,51 (3,39 – 3,54) 3,65 (3,5 – 3,69) 0,0723 
Cortical RF thickness 
(mm) 
65 (63,5 – 66,75) 63 (61,5 – 65) 0,3277 
Cortical LF thickness 
(mm) 
65 (61,5 – 67) 63,5 (62,75 – 64,25) 0,4831 
Maximal load of the right 
femoral shaft (N) 
191 (183,75 – 213,5 183 (179,25 – 191,25) 0,1444 
Maximal load of the left 
femoral shaft (N) 
190,5 (177,25 – 222,5) 199 (191- 217) 0,9283 
Maximal load of the right 
femoral neck (N) 
124,5 (121,75 – 133,25) 152,43 (136- 166) 0,1281 
Maximal load of the left 
femoral neck (N) 
124 (111 – 133,5) 150,5 (130 – 165) 0,0887 
Tab. 29 Biomechanical and geometric parametrs. Data are expressed as median (25 th – 75 th 






The effect of trazodone on rat bone metabolism 
Serum concentrations of drugs 
At the end of experiment the level of trazodone in the TRA-ORX group was 
0,6 (0,5 – 0,625 mg/L), equivalent to therapeutic levels of the drug 0,5 – 2,5 
mg/L.  
Weight and body composition 
DEXA revealed that the experimental group showed a decrease in fat 
mass versus the control group. There were no significant differences in lean 
body mass between the experimental group and the control group (Table 30).  
Levels of bone markers 
The levels of OPG and BALP were decreased. The levels of sclerostin 
were increased. The results from the ELISA determination are shown in table 
31.  
Dual Energy X-Ray Absorptiometry 
There were no significant differences in BMD and BMC between the 
experimental group and the control group. The results are shown in Table 32.  
Biomechanical Properties 
There were no significant differences in biomechanical testing 
measurement between the experimental group and the control group. The 








Parameter TRA-ORX CON-ORX p-value 
Final body weight (g) 528 (492,75 – 558,25) 474 (460,25 – 490) 0,1085 
Fat (g) 65,7  (62,68 – 70) 103,85 (80 – 114,4)* 0,0029 
Lean body mass (g) 311,5 (305 – 323,5) 285,4 (278,6 – 303,3) 0,0870 
Tab. 30 Body weight and fat mass. Data are expressed as median (25 th – 75 th percentiles), 
n=8; *p < 0.05. 
 
Parameter TRA-ORX CON-ORX p-value 
BALP (ng/ml) 5,81 (5,64 – 6,46) 20,09 (17,21 – 20,51)* 0,0028 
P1NP (pg/ml) 224,49 (200,89 – 248,29) 217,21 (164,71 - 248,82) 0,4487 
OPG (pg/ml) 1,35 (1,26 – 1,41) 1,92 (1,56 – 2,08)* 0,0014 
Sclerostin (ng/ml) 0,416 (0,354 – 0,460) 0,268 (0,221 – 0,279)* 0,0095 
BMP (pg/ml) 2128 (19,81 – 23,39) 25,14(21,78 – 26,65) 0,1652 
CTX-I (pg/ml) 61,37 (54,88 – 70,82) 68,27 (48,72 - 78,41) 0,4302 
Tab. 31 Levels of bone markers. Data are expressed as median (25 th – 75 th percentiles), n=8; 









BMD(g/cm2) TRA-ORX CON-ORX p-value 
Whole body  0,164 (0,160 – 0,166) 0,164 (0,161 - 0,167) 0,8016 
Diaphysis right femur 0,174 (0,170 – 0,177) 0,181 (0,167 - 0,184) 0,7774 
Diaphysis left femur 0,166 (0,157 – 0,169) 0,176 (0,164 – 0,182) 0,1715 
Lumbar columna (L3-L5) 0,207 (0,202 – 0,210) 0,203 (0,193 - 0,213) 0,7589 
Tab. 32 Densitometric parameters. Data are expressed as median (25 th – 75 th percentiles), n 
= 8; *p < 0.05. 
 
Parameter TRA-ORX CON-ORX p-value 
RF length (mm) 37,23 (36,69 – 37,66) 37,31 (36,58 – 37,96) 0,6571 
LF length (mm)  37,73 (36,83 – 37,83) 37,22 (36,88 – 37,67) 0,6598 
RF diameter (mm) 3,62 (3,53 – 3,67) 3,71 (3,58 – 3,88) 0,2891 
LF diameter (mm) 3,7 (3,54 – 3,76) 3,65 (3,5 – 3,69) 0,7910 
Cortical RF thickness 
(mm) 
62,5 (59,75 – 64,5) 63 (61,5 – 65) 0,8106 
Cortical LF thickness 
(mm) 
63,5 (62,75 – 64,25) 64 (62 – 64) 0,6601 
Maximal load of the right 
femoral shaft (N) 
183 (179,25 – 191,25) 204 (196 – 208) 0,1234 
Maximal load of the left 
femoral shaft (N) 
206,5 (203 – 214,25) 199 (191- 217) 0,4726 
Maximal load of the right 
femoral neck (N) 
124 (113,5 – 144,5) 152,43 (136- 166) 0,2796 
Maximal load of the left 
femoral neck (N) 
141( 128,75 – 154) 150,5 (130 – 165) 0,3937 
Tab. 33 Biomechanical and geometric parameters. Data are expressed as median (25 th – 75 th 




Parameter MIRTA-ORX ORX VENLA-ORX TRA-ORX CON-ORX 
P1NP (pg/ml) 201,92 (182,58 – 235,28) 210,21 (175,53 – 261,09) 224,49 (200,89 – 248,29) 217,21 (164,71 - 248,82) 
BALP (ng/ml) 18,31 (17,04 - 22,30)* 7,15 (5,60 – 8,87)*** 5,81 (5,64 – 6,46)*** 20,09 (17,21 – 20,51) 
OPG (pg/ml) 1,44 (1,32 – 1,55)* 1,64 (1,53 – 1,85) 1,35 (1,26 – 1,41)** 1,92 (1,56 – 2,08) 
Sclerostin (ng/ml) 0,344 (0,288 – 0,381) 0,457 (0,405 – 0,484) 0,416 (0,354 – 0,460) 0,268 (0,221 – 0,279) 
CTX-I (pg/ml) 58,79 (55,62 – 60,64) 99,54 (79,09 – 110,30) 61,37 (54,88 – 70,82) 68,27 (48,72 - 78,41) 
BMD whole body (g/cm2) 0.159 (0.158–0.166) 0,158 (0156 – 0,165) 0,164 (0,160 – 0,166) 0,164 (0,161 – 0,167) 
BMD RF (g/cm2) 0.171 (0.159–0.175) 0,161 (0,158 – 0,166) 0,174 (0,170 – 0,177) 0,181 (0,167 – 0,184) 
BMD LF (g/cm2) 0.161 (0.158–0.168) 0,154 (0,151 – 0,157) 0,166 (0,157 – 0,169) 0,176 (0,165 – 0,185) 
Maximal load of the right femoral shaft (N) 196 (188–203.5) 191 (183,75 – 213,5) 183 (179,25 – 191,25) 204 (196 – 208) 
Maximal load of the left femoral shaft (N) 201.5 (184.5–220.5) 190,5 (177,25 – 222,5) 206,5 (203 – 214,25) 199 (191- 217) 
Maximal load of the right femoral neck (N) 132 (123.7–137.5)* 124,5 (121,75 – 133,25) 124 (113,5 – 144,5) 152,43 (136- 166) 
Maximal load of the left femoral neck (N) 133 (126.5–146.5)* 124 (111 – 133,5) 141( 128,75 – 154) 150,5 (130 – 165) 
Tab.  34  Comparison of chosen parameters in all selected antidepressant drugs to the control group   





The increase in life expectancy of the world population is associated with 
challenges regarding health issues. For instance, osteoporosis is a medical condition 
mostly observed in elderly people, in which the quality and quantity of the bone are 
severely affected. Not only for women but also for men, osteoporosis is recognized 
as an important public health issue (Alghamdi HS, et al., 2014). ). Osteoporotic 
fractures are a significant cause of morbidity and mortality (Wheater G, et al., 2013). 
8.1. The effect of orchidectomy on rat bone mass, structure 
and metabolism 
Research on osteoporosis has so far been primarily performed on 
postmenopausal women, due to the high incidence of disease in this population. 
However, it is important to acknowledge that also men who had undergone spinal 
surgery had osteoporosis, which can result in higher reported morbidity. For this 
reason, research on male osteoporosis is essential (Ryu SJ, et al., 2015). We found 
in rats 12 weeks post-orchidectomy a significant decrease in body weight, bone 
mineral density and lean body mass, and an increase in fat mass. These results 




negatively affects body composition, and establishes these animals as suitable 
models for investigating androgenic modulation of body composition 
(Vanderschuerenet D, et al., 2000; Gentile MA, et al., 2010). 
8.2. The effect of the selected newer antiepileptic drugs on 
bone metabolism 
Since the end of the 1960s, the effect of antiepileptic agents on bone has been 
examined in a number of papers. However, in the case of the novel antiepileptics, 
data are scarce: there are no prospective studies with a sufficiently long period of 
monitoring. The exact mechanism of action of selected antiepileptics (LEV, LCM, 
LTG, TPM) is yet to be defined. There are several anticipated mechanisms of 
action:  changes in γ-aminobutyric acid (GABA) metabolism and turnover; 
inhibition of the excitatatory system (mainly glutamate); inhibition of 
neurotransmission by modulation of voltage-controlled sodium channels; and 
inhibition of T-type calcium channels (Walker MC and Sander JW, 1999; Dooley 







The effect of levetiracetam on rat bone mass 
We found that long-term LEV treatment significantly reduced BMD of the left 
femoral diaphysis. We observed a significant fall in OPG, and an increase in CTX-I of 
borderline statistical significance. No significant differences in biomechanical or 
geometric parameters of rat right and left femurs were observed. Adipose tissue 
significantly decreased in both absolute and relative terms, while body weight 
decreased at borderline statistical significance.  
There are only a few and conflicting data in the literature concerning the effect 
of LEV on BMD. Nissen-Meyer and co-workers have reported in rats that LEV did not 
alter bone mass as judged by unaltered BMC and BMD. That paper suggests a dose-
dependent (biphasic) effect of LEV on bone. Only low dose LEV (serum 
concentration 122 ± 41 umol/l) was associated with reduced biomechanical strength 
and reduced levels of serum osteocalcin, a marker of bone formation, but not high 
dose (serum LEV concentration 277 ± 65 umol/l). Their results suggest LEV may 
have a harmful effect on trabecular bone rather than cortical bone, which would be 
manifested in a change in BMD. Compared to this previous study (Nissen-Meyer LS, 
et al., 2007), our results suggest that in the ORX-rat model LEV may affect bone 
mass of the femoral diaphysis (cortical bone). The serum LEV concentration in our 
study (201.62 [191.9025–217.815] umol/l) was comparable to that reported in the 
high-dose group in the previous study (Nissen-Meyer LS, et al., 2007). However, 
because LEV was administered in different ways (SLD enriched with LEV ad 




paper), and since we don’t know the timing of blood sampling relative to drug 
administration in Nissen-Meyer's paper, there is limited validity in comparing plasma 
concentrations of LEV between the two studies. Our results (in regard to OPG and 
CTX-I levels) suggest that LEV may suppress bone turnover. We may assume that 
the reduction in serum OPG levels could be explained by the inhibition of osteoblast 
activity. 
In research on humans, there have been conflicting reports on bone strength 
and metabolism. One retrospective cross-sectional study suggested that LEV is more 
often associated with decreased BMD compared to the other AEDs (carbamazepine, 
valproic acid, lamotrigine, topiramate) (Beniczky SA, et al., 2012). However, this 
study did not measure baseline BMD before AED administration. Thus the findings of 
cross-sectional studies may be affected by the differences in baseline BMD amongst 
study subjects and by other factors such as past intake of other AEDs, physical 
activity, diet, and sun exposure. Contrary to this, a recent prospective study found no 
significant changes in BMD of the femoral neck, total femur or lumbar spine after LEV 
administration of mean duration 14.16 ± 3.36 months. Biochemical bone markers 
(calcium, phosphorus, 25-hydroxyvitamin D, alkaline phosphatase, bone alkaline 
phosphatase, parathyroid hormone, osteocalcin, CTX-I, insulin-like growth factor-1) 
also showed no significant change (Koo DL, et al., 2013). Traditionally, attention to 
the problem of AED-induced bone loss has been focused on those drugs that induce 
the hepatic cytochrome P450 enzyme system, thereby increasing the metabolism of 




multiple, including the effects of AEDs on sex-steroid hormones (Pack A, 
2008; Isojarvi JI, et al., 2005; Rattya J, et al., 2001 and Pack AM, et al., 2011). There 
is one animal study which reports a significant decrease in estradiol level after LEV 
administration (Svalheim S, et al., 2008). 
In the ORX rat model estrogen was more effective in preventing ORX-induced 
bone loss than androgen action (Vandenput L, et al., 2002). This finding is supported 
by both animal and human data, which indicate that estrogens play a crucial role in 
regulating the male skeleton (Callewaert F, et al., 2010). Although underlying 
mechanisms of the effect of LEV on bone are still unclear, LEV-mediated decrease of 
estrogen levels could represent one of the relevant mechanisms of bone loss. 
In conclusion, administration of LEV in the ORX rat model can have a negative 
effect on bone as judged by reduced femoral BMD, decreased serum levels of OPG 
(a marker of bone formation) and increased levels of CTX-I (a marker of bone 
resorption), but this study failed to show any change in femoral bone geometry or 
biomechanical bone strength. Administration of LEV in the ORX-rat model may 
reduce adipose tissue.  
 
The effect of lacosamide on rat bone mass 
The effect of LCM on bone tissue has not yet been investigated, except for 
studies in juvenile dogs (published only in the form of an abstract) (Cornet M, et al., 




osteoporosis in experimental animals (Gentile MA, et al., 2010). 
LCM-ORX had significant loss of BMD at the left and right femur after 12 
weeks when compared to the control (CON-ORX). However, no significant 
differences in biomechanical and geometric parameters of rat right and left femurs 
were observed. Evaluation of bone turnover using biochemical markers specific for 
both bone formation (BALP, BMP-2, P1NP, OPG, IGF-1) and bone resorption (CTX-I) 
was without significant difference with the exception of P1NP.  
We have noticed a significant change in the P1NP, which is a marker of bone 
formation, which was significantly lower in LCM-ORX. To our knowledge, no studies 
have been published with AEDs (or with CYP2C19 inhibitors) in which changes in the 
level of P1NP were monitored. Some further research will be necessary to verify the 
role and the importance of P1NP in the diagnosis, and more precisely in the 
pathophysiology of AEDs-O. We have discovered only one prospective study testing 
the influence of LCM on BMD in gonadally-intact subjects, in which the authors claim 
an absence of influence of LCM on BMD (Cornet M, et al., 2010). However, we have 
monitored a significant decline of BMD at the left and right femur.  We assume then 
that long-lasting exposure to LCM can represent a certain risk to the health of bone in 
the setting of gonadal insufficiency. It is complicated to determine how high the risk 
will be in comparison to the other AEDs.  
The mechanism of the effect of LCM on bone is unclear. LCM has been shown 




the suppression ratio in a conditioned emotional response test, and reduced the 
number of marbles buried in the marble burying assay (Higgins GA, et al., 2009; 
Horcajada-Molteni MN, et al., 1999). In rodents, physical activity prevents decrease 
in BMD as it does in humans, which suggests that increased physical activity could 
be useful in the prevention of bone mineral loss, regardless of gonadal hormone 
deficiency (Horcajada-Molteni MN, et al., 1999). Therefore reduced locomotor activity 
could be the factor contributing to significant decrease in LF-BMD and RF-BMD in 
LCM-ORX compared to CON-ORX. 
 
The effect of topimarate on rat bone mass 
There was a significant decrease in whole-body BMD and that of the femurs, 
but no significant changes in bone turnover markers were observed.  
As far as the present authors know, the first mention of a possible risk of TPM 
for bone in connection with treatment with AEDs is in a study dealing with an analysis 
of a cohort of 96 epileptics of childhood or juvenile age. Besides other things, the 
authors report a significant correlation of the presence of TPM in medication with an 
abnormal value of BMD (Coppola G, et al., 2009). A possible negative effect of TPM 
on bone tissue is also suggested by the results of a pilot study examining the BMD of 
the lumbar spine and hip in 19 women receiving prophylactic TPM medication for 




months; average dose of TPM, 136 mg). In 8 female patients (53%) the T-score was 
abnormal, i.e. in the range of osteopenia (Vega D, et al., 2007). Nevertheless, the 
results of the study were limited, not least because of the absence of a control group. 
TPM, as well as zonisamide and sulthiame are all inhibitors of carbonic anhydrase. 
Inhibition of carbonic anhydrase is the cause of metabolic acidosis in a large number 
of both children and adults medicated with TPM (Belcastro V, et al., 2010). Besides 
metabolic acidosis, hyperhomocysteinemia and a deficit of vitamin B12 may exert a 
negative effect on bone health (Linnebank M, et al., 2011; Anderson GD, 2004).  
The weight of the rats in the experimental group decreased in a statistically 
significant manner.  There were significant decreases in fat mass and lean body 
mass. The finding is in agreement with the literature data (Merideth Ch, 2006). As far 
as the markers of bone turnover are concerned, the significance of bone turnover 
markers for the diagnosis of antiepileptic drug-induced osteopathy is controversial: 
although PHT is well-known to cause significant losses of BMD and BMC, only 
modest changes in the markers of bone turnover have been observed in animals 
(Moro-Alvarez MJ, et al., 2009; Onodera K, et al., 2001; Valimaki MJ, et al., 1997). 
Similarly, in a longitudinal study of premenopausal women treated with PHT, bone 
turnover markers remained unchanged after 1 year, except for a significant decline in 
urine N-telopeptide. This result is unclear and difficult to explain, particularly in view 
of the significant observed femoral neck bone loss (Pack AM, et al., 2008). 
Conflicting data exist regarding the effects of CBZ on BMD and bone turnover (Sheth 




al., 2001). VPA in animals reduced BMD and BMC and increased bone turnover 
(Moro-Alvarez MJ, et al., 2007); there are mixed data in humans. Some have 
observed that VPA monotherapy resulted in decreased BMD and increased 
significantly markers of both bone formation and resorption (Verrotti A, et al., 2010; 
Zhang J, et al., 2010), but in the longitudinal study of young women mentioned 
above, the BMD was stable and bone turnover markers remained unchanged after 1 
year of VPA treatment (Pack AM, et al., 2008).  
Data for TPM are scarce.  In a cohort of long-term patients treated with TPM 
monotherapy, significantly lower serum levels of calcium, parathormone and 
bicarbonates were found. Laboratory markers of increased bone turnover were also 
found: an increased level of osteocalcin, bone isoenzyme of alkaline phosphatase 
and CTX-I (Heo K, et al., 2011). A Chinese study in 2010, on the other hand, 
reported a significantly higher level of calcium in the serum without significant 
differences in the serum content of alkaline phosphatase (Zhang J, et al., 2010). 
In summary, TPM can significantly reduce BMD and body weight. Besides the 
issues concerning the pathogenesis of the effect of TMP on bone, further studies 
need to address the question as to what extent the effect found by the present 
authors is dependent on the dose, or on the serum levels of TPM, in order to 






The effect of lamotrigine on rat bone mass 
The treatment with LTG resulted in a significant decrease in whole-body BMD 
and that of the femurs. Testing of the mechanical strength of the bone tissue by 
means of three-point bending revealed a statistically significant decrease in the 
maximal load values in experimental groups versus the control group. No significant 
changes in bone turnover markers were observed.   
LTG is an inducer of UGT enzymes. Isoenzymes of the families UGT1 and 
UGT2 play an important role in the metabolism of xenobiotics as well as in that of a 
number of endogenous substances such as steroidal hormones, hormones of the 
thyroid gland, fat-soluble vitamins, bilirubin and biliary acids (Ohta T, et al., 1995). 
This mechanism could be relevant to the effect of LTG on bone health. The level of 
LTG in the present author’s study was found to be above the therapeutic range for 
human use: 77,74 (72,28 – 84,22) µmol/L, while that of TPM was at the lower limit of 
the therapeutic range for human use: 22,04 (21,64 – 22,71) µmol/L. It is therefore 
possible that a more marked negative effect of LTG on the bone could be associated 
with the relatively high level of the drug in the serum. A dose-dependent effect in 
connection with the effect of AEDs on bone has been reported also for phenytoin. At 
low doses this drug, which is typically a risk agent for bone, is reported to have an 
osteogenic effect (Richard D, et al., 2002).  
The weight of the rats in the experimental groups decreased in a statistically 




(Merideth CH, 2006). A reduction in weight after exposure to LTG was, however, 
reported in both people and animals (Daoud AS, et al., 2004; Nissen-Meyer LS, et 
al., 2007).  The present authors presume that the greater effect of LTG on weight as 
found in the present paper may be connected with the previously-mentioned 
difference in the serum levels of the drug. 
As far as the markers of bone turnover are concerned, the significance of bone 
turnover markers for the diagnosis of antiepileptic drug-induced osteopathy is 
controversial: although PHT is well-known to cause significant losses of BMD, only 
modest changes in the markers of bone turnover have been observed in animals 
(Moro-Alvarez MJ, et al., 2009; Onodera K, et al., 2001; Valimaki MJ, et al., 1994). 
Similarly, in a longitudinal study of premenopausal women treated with PHT, bone 
turnover markers remained unchanged after 1 year, except for a significant decline in 
urine N-telopeptide. This result is unclear and difficult to explain, particularly in view 
of the significant observed femoral neck bone loss (Pack A, 2008). Conflicting data 
exist regarding the effects of CBZ on BMD and bone turnover (Sheth RD end 
Hermann BP, 2007; Pack AM, et al., 2008; Sato Y, et al., 2001). VPA in animals 
reduced BMD and BMC and increased bone turnover (Moro-Alvarez MJ, et al., 
2009); there are mixed data in humans. Some have observed that VPA monotherapy 
resulted in decreased BMD and increased significantly markers of both bone 
formation and resorption (Valimaki MJ, et al., 1994; Verrotti A, et al., 2002), but in the 
longitudinal study of young women mentioned above, the BMD was stable and bone 




al., 2008).  
Data for LTG are scarce.  So far LTG has not been shown to cause significant 
effects on BMD and bone turnover (Sheth RD end Hermann BP, 2007; Pack AM, et 
al., 2008), except for a significantly increased level of osteocalcin, a marker of bone 
formation, referred in one study (Kim SH, et al., 2007). 
In summary, LTG can significantly reduce BMD and body weight, and impair 
the mechanical strength of the bone. Beside the issues concerning the pathogenesis 
of the effect of LTG on the bone, further studies need to address the question as to 
what extent the effect found by the present authors is dependent on the dose, or on 
the serum levels of LTG, in order to determine if it is necessary to monitor, besides 
BMD, also the levels of this antiepileptic agent. 
 
In conclusion, we have confirmed a BMD reduction in all 4 medications in the 
tested group. The negative effect was the greatest in lamotrigine and decreased 
sequentially in lacosamide, topiramate and levetiracetam. Lamotrigine also caused a 





8.3. The effect of the selected newer antidepressant drugs 
on rat bone metabolism 
The link between depression, antidepressant use, and osteoporosis is becoming 
more widely understood, and there is mounting evidence for the influence of 
depression and antidepressants on fracture rates (Rizzoli R, et al., 2012). However, 
reports examining the relationship between SSRIs and bone mass and remodelling 
have yielded inconsistent results. Serotonin is a neurotransmitter that is primarily 
found in the gastrointestinal (GI) tract, central nervous system (CNS) and platelets. 
Serotonin plays an important role in mood regulation, and selective serotonin 
reuptake inhibitors (SSRIs) are widely used psychotropic medications prescribed for 
the treatment of depression and anxiety. Recent animal and in vitro studies support a 
role for serotonin in the regulation of bone mass and remodelling (Feuer AJ, et al., 
2015).  
For this study we have chosen selected new antidepressant drugs in which the 
effect on bone metabolism has not yet been sufficiently investigated. To our 
knowledge, this study is the first clinical research with the aim of examining the 
effects of these antidepressant drugs on bone metabolism in rats. Mirtazapine is a 
member of the noradrenergic and specific serotonergic antidepressant group 




trazodone is a selective serotonin reuptake inhibitor (SSRI). 
The effect of mirtazapine on rat bone mass 
We discovered that mirtazapine, which is a norepinephrine and specific 
serotonergic antidepressant (NaSSA), has a negative influence on BMD and reduces 
the mechanical strength of bones in the femoral neck region. In rodents, physical 
activity prevents decrease in BMD as it does in humans, which suggests that 
increased physical activity could be useful in the prevention of bone mineral loss, 
regardless of gonadal hormone deficiency (Horcajada-Molteni MN, et al., 1999). 
Therefore reduced locomotor activity could be the factor contributing to significant 
decrease in LF-BMD and RF-BMD in MIRTA-ORX compared to the ORX group.  
There was a significant decrease compared to the ORX group in the levels of 
BALP and OPG, both of which are markers of bone formation. In addition, there was 
a significant increase in levels of sclerostin that inhibits activation of osteoblasts. 
Accordingly, our findings suggest that increased bone loss with serotonin-
norepinephrine antidepressants is mediated via decreased bone formation. 
Our findings for OPG, BALP and sclerostin suggest that mirtazapine may 
suppress bone turnover. We may assume that the reduction in OPG and BALP levels 
could be explained by the inhibition of osteoblast activity. In conclusion, long-term 
administration of mirtazapine in the ORX-rat model can have a negative effect on 




decreased levels of OPG and BALP (markers of bone formation), and increased 
levels of sclerostin may cause deterioration of the mechanical strength of the bone.  
 
The effect of venlafaxine on rat bone mass 
 We found that treatment with venlafaxine, a serotonin–norepinephrine 
reuptake inhibitor, was associated with increased levels of CTX-I, a marker of bone 
resorption, without a compensatory increase in P1NP, but there were decreased 
levels of BALP, a marker of bone formation and mineralization. Our findings suggest 
that the increased rate of bone loss with venlafaxine is mediated via increased bone 
resorption and also decreased osteoblast differentiation.  Among other things, we 
found increased levels of sclerostin. Thus we confirm the results of previous studies 
(Shea ML, et al., 2013; Haney EM, et al., 2007; Cauley JA, et al., 2005; Richards JB, 
et al., 2007; Warden JS, et al., 2010; Warden JS, et al., 2008). Serotonergic 
antidepressants may increase bone resorption via the serotonin transporter or other 
types of serotonin receptors (Battaglino R, et al., 2004). At the same time, inhibition 
of the 5-HTT may have significant damaging effects on bone mineral deposition in 
the growing mouse skeleton (Warden JS, et al., 2010).  
Decreased  levels of BALP (markers of bone formation) and increased levels 
of CTX-I and  sclerostin and last but not least, reduced bone density in the diaphysis 




The effect of trazodone on rat bone mass 
Trazodone is a triazolopyridine antidepressant with relatively small effects on 
cholinergic conduction. It is an effective antidepressant drug with a broad therapeutic 
spectrum, including anxiolytic and sedative effect. Although trazodone is usually 
referred to as an SSRI, it may have other pharmacological effects (Albertazzi P, 
2006). Since the advent of the selective serotonin re-uptake inhibitors, there have 
been data concerning hormonal effects of particular relevance to women, specifically 
raised prolactin levels, which may vary from antidepressant to antidepressant. It has 
been suggested that the use of antidepressants decreases bone mineral density 
(BMD) more than is normal for the age and sex of patients, and increases the risk for 
fractures (Laekeman G, et al., 2008). 
There was a significant decrease compared to the control group in the levels 
of OPG and BALP while levels of sclerostin were significantly increased.  Other 
results (Shea ML, et al., 2013) have suggested that the primary effect of serotonergic 
antidepressants is the increase in bone resorption. Our findings for OPG, BALP and 
sclerostin suggest that trazodone may suppress bone turnover. We may assume that 
the reduction in OPG and BALP levels and increase in sclerostin levels could be 






In conclusion, the tested groups as a whole demonstrated a negative effect on 
bone metabolism. We confirmed a reduction of osteoblastic activity in all 3 
medications. However there are differences between individual drugs in the extent of 
the negative effect. The greatest effect was observed in trazadone. Moreover tests of 















1   a)  Our set goal was to determine the effect of orchidectomy on bone  
metabolism in rats.  
We found that after 12 weeks post-orchidectomy there was a negative 
effect on bone metabolism in rats. These results established these animals as 
suitable models for investigating androgenic modulation of body composition. 
 
2  a) A second goal was to determine the effect of selected antiepileptic 
drugs (levetiracetam, lacosamide, topiramate, lamotrigine) on bone metabolism 
in rats.  
We determined that long-term administration of levetiracetam, 
lacosamide and topiramate can have a negative effect as judged by reduced 
femoral BMD. However, after 12 weeks the results showed no reduction of 
biomechanical bone strength. On the other hand, as well as a reduction in 
BMD, long-term administration of lamotrigine resulted in impairment of the 






b)  We also wanted to determine the extent of the (negative) effect of 
selected antiepileptic drugs in comparison to the control group.  
We detected a negative effect in all selected antiepileptic drugs. The 
extent of the negative effect was greatest for lamotrigine, and decreased 
sequentially in lacosamide, topiramate and levetiracetam. 
 
3  a)  Another objective was to determine the effect of selected 
antidepressant drugs (mirtazapine, venlafaxine, trazodone) on bone metabolism 
in rats.  
Our findings after 12 weeks suggest that administration of mirtazapine 
may suppress bone turnover, especially in the femoral neck. Long-term 
administration of venlafaxine and trazodone indicated inhibition of osteoblast 
activity.  
 
b)  Finally we were interested in the extent of the (negative) effect of 
selected antidepressant drugs in comparison to the control group.  
In all the selected antidepressant drugs we determined a verifiable 
negative effect on bone metabolism in rats. However there were differences 




activity was impaired the most by trazodone and least by mirtazapine. 
Surprisingly in mirtazapine, we also confirmed the highest reduction in femoral 

















Alam A, Voronovich Z, Carley JA. A review of therapeutic uses of mirtazapine in 
psychiatric and medical conditions. Prim Care Companion CNS Disord. 2013;15(5). 
 
Albertazzi P. Noradrenergic and serotonergic modulation to treat vasomotor 
symptoms. J Br Menopause Soc. 2006; 12(1): 7-11. 
 
Alghamdi HS, van den Beucken JJ, Jansen JA. Osteoporotic rat models for 
evaluation of osseointegration of bone implants. Tissue Eng Part C Methods. 2014; 
20(6): 493-505.  
 
Ali II, Herial NA, Orris M, et al. Migraine prophylaxis with topiramate and bone health 
in women. Headache. 2011; 51(4): 613-616. 
 
Anderson GD. Pharmacogenetics and enzyme induction/ inhibition properties of 
antiepileptic drugs. Neurology. 2004; 63: 3-8. 
 
Anwar MJ, Radhakrishna KV, Vohora D. Phenytoin and sodium valproate but not 
levetiracetam induce bone alterations in female mice. Can J Physiol 
Pharmacol. 2014; 92(6): 507-511. 
 
Battaglino R, Fu J, Spate U, et al. Serotonin regulates osteoclast differentiation 





Beniczky SA, Viken J, Jensen LT, et al. Bone mineral density in adult patients treated 
with various antiepileptic drugs. Seizure. 2012; 21(6), 471-472. 
 
Belcastro V, Striano P, Gorgone G, et al. Hyperhomocysteinemia in epileptic patients 
on new antiepileptic drugs. Epilepsia. 2010; 51(2): 274-279. 
 
Bhattoah HP, Wamwaki J, Kalina E, et al. Serum sclerostin levels in healthy men 
over 50 years of age. J Bone Miner Metab. 2013;  31(5): 579-584. 
 
Borges NC, Barrientos-Astigarraga RE, Sverdloff CE, et al. A fast, sensitive and 
simple method for mirtazapine quantification in human plasma by HPLC-ESI-MS/MS. 
Application to a comparative bioavailability study. Biomed. Chromatogr. 2012; 26 
(11): 1399-1407. 
 
Bruyère O, Reginster JY. Osteoporosis in patients taking 
selective serotonin reuptake inhibitors: a focus on fracture outcome. Endocrine. 2014; 
48(1), 65 – 68. 
 
Callewaert F, Sinnesael M, Gielen E, et al. Skeletal sexual dimorphism: relative 
contribution of sex steroids, GH-IGF1, and mechanical loading. J Endocrinol. 2010; 
207(2): 127-134. 
 
Carbone LD, Johnson KC, Robbins J, et al. Antiepileptic drug use, falls, fractures, 




initiative (WHI). J Bone Miner Res. 2010; 25(4):873-81. 
 
Cauley JA, Fullman RL, Stone KL, Zmuda, et al. Factors associated with the lumbar 
spine and proximal femur bone mineral density in older men. Osteoporos Int. 2005; 
16: 1525–1537. 
 
Compston JE. Sex Steroids and Bone. Physiological Reviews. 2001; 81 (1): 419-447.  
 
Compton JT, Lee YF. A review of osteocyte function and the emerging importance of 
sclerostin. J Bone Joint Surg. 2014; 96 (19): 1659–1668. 
 
Coppola G, Fortunato D, Auricchio G, et al. Bone mineral density in children, 
adolescents, and young adults with epilepsy. Epilepsia. 2009; 50(9): 2140-2146. 
 
Cornet M, Tytgat D, Léonard M. Lacosamide does not alter bone densitometry 
parameters in juvenile dogs. Abst. 2.191, 2010. 
 
Daoud AS, Bataineh H, Otoom S, et al. The effect of Vigabatrin, Lamotrigine and 
Gabapentin on the fertility, weights, sex hormones and biochemical profiles of male 
rats. Neuro Endocrinol . 2004; 25(3):178-183. 
 
Dooley M, Plosker GL. Levetiracetam. A review of its adjunctive use in the 




Dunitz M. Osteoporosis: Diagnosis and managment. London: Martin Dunitz 
LTD,1998. ISBN 1-85317-613-3. 
 
Dunitz M. Bone markers, biomechanical and clinical perspectives. London: Martin 
Dunitz LTD, 2001. ISBN 1-841184-067x. 
 
Ebrahimi F, Ebrahimitalab A, Es'haghi Z. Magnetized silane-coupling agent KH-570 
based solid-phase extraction followed by gas chromatography-flame ionization 
detection to determine venlafaxine in human hair and aqueous environmental 
samples. Arch Environ Contam Toxicol. 2015; 68(2): 412-420.  
 
Emerton KB, Hu B, Woo AA, et al. Osteocyte apoptosis and control of bone 
resorption following ovariectomy in mice. Bone. 2010; 46 (3): 577–583. 
 
Engel J, Pedley TA. Epilepsy a comprehensive text book. USA: Lippincott 
Williams&Wilkins, 2008. ISBN 0-7817-5777-0. 
 
Eskandari F, Martinez PE, Torvik S, et al. Low bone mass in premenopausal women 
with depression. Arch Intern Med. 2007; 167: 2329–2336. 
 
Feuer AJ, Demmer RT, Thai A, et al. Use of selective serotonin reuptake inhibitors 





Florencio-Silva R, da Silva Sasso GR, Sasso-Cerri E, et al. Biology of Bone Tissue: 
Structure, Function, and Factors That Influence Bone Cells. BioMed Research 
International. 2015;  Epub. doi: 10.1155/2015/421746. 
 
Gentile MA, Nantermet PV, Vogel RL, et al. Androgen-mediated improvement of 
body composition and muscle function involves a novel early transcriptional program 
including IGF-1, mechano growth factor, and induction of  {beta}-catenin. J Mol 
Endocrinol. 2010; 44: 55–73. 
 
Giannopoulou EZ, Gortner L, Peterlini S, et al. Topiramate-induced nephrolithiasis. 
Clin Case Rep. 2015; 3(6): 508-509. 
 
Greenaway C, Ratnaraj N, Sander JW, et al. A High-performance liquid 
chromatography assay to monitor the new antiepileptic drug lacosamide in patients 
with epilepsy. Ther Drug Monit. 2010; 32(4): 448-452. 
 
Halford JJ, Lapointe M. Clinical Perspectives on Lacosamide. Epilepsy Currents. 
2009; 9(1): 1–9. 
 
Hammad LF. Bone mineral density in university aged Saudi females. Pak J Med Sci. 
2015; 31(3): 556–560. 
 
Haney EM, Chan BK, Diem, SJ, et al. Association of low bone mineral density with 






Heo K, Rhee Y, Lee HW, et al. The effect of topiramate on bone mineral density and 
markers of bone mineral metabolism in premenopausal women with epilepsy. 
Epilepsia. 2011; 52(10): 1884-1889.   
 
Higgins GA, Breysse N, Undzys E, et al. The anti-epileptic drug lacosamide (Vimpat) 
has anxiolytic property in rodents. Eur J Pharmacol. 2009; 624(1-3):1-9. 
 
Horcajada-Molteni MN, Davicco MJ, Coxam V, et al. Treadmill running starting 3 
months after orchidectomy restores femoral bone mass in rats. Eur J Appl Physiol 
Occup Physiol. 1999; 79(3): 251-259. 
 
Isojarvi JI, Tauboll E, Herzog AG. Effect of antiepileptic drugs on reproductive 
endocrine function in individuals with epilepsy. CNS Drugs. 2005; 19(3): 207-223. 
 
Johannessen LC, Larsson PG, Rytter E, et al. Antiepileptic drugs in epilepsy and 
other disorders -- a population-based study of prescriptions. Epilepsy Res. 2009; 
87(1): 31-39. 
 
Kanis JA. Osteoporosis. Oxford: Blackwell science LTD, 1994. ISBN 0-632-03811-x. 
 
Kim SH, Lee JW, Choi KG, et al. A 6-month longitudinal study of bone mineral 





Kini U, Nandeesh BN. Physiology of bone formation, remodeling, and metabolism, 
Berlin: Springer-Verlag Berlin Heidelberg, 2012. ISBN 978-3-642-02399-6. 
 
Koo DL, Joo EY, Kim D, et al. Effects of levetiracetam as a monotherapy on bone 
mineral density and biochemical markers of bone metabolism in patients with 
epilepsy. Epilepsy research. 2013; 104 (1-2): 134-139. 
 
Kousteni S, Chen JR, Bellido T,et al. Reversal of bone loss in mice by nongenotropic 
signaling of sex steroids. Science. 2002; 298 (5594): 843–846.  
 
Laekeman G, Zwaenepoel L, Reyntens J, et al. Osteoporosis after combined use of a 
neuroleptic and antidepressants. Pharm World Sci. 2008; 30(5): 613-616. 
 
Lancelin F, Franchon E, Kraoul L, et al. Therapeutic drug monitoring of levetiracetam 
by high-performance liquid chromatography with photodiode array ultraviolet 
detection: preliminary observations on correlation between plasma concentration and 
clinical response in patients with refractory epilepsy. Therap Drug Monit. 2007; 29(5): 
576-583. 
 
Lang DG, Wang CM, Cooper BR. Lamotrigine, phenytoin and carbamazepine 
interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J 
Pharmacol Exp Ther. 1993; 266: 829–885. 
 
Lazzari AA, Dussault PM, Thakore-James M, et al. Prevention of bone loss and 
vertebral fractures in patients with chronic epilepsy—Antiepileptic drug and 





Linnebank M, Moskau S, Semmler A, et al. Antiepileptic drugs interact with folate and 
vitamin B12 serum levels. Ann Neurol. 2011; 69(2): 352-359. 
 
Levy RH, Mattson RH, Meldrum BS, Perucca E. Antiepileptics drugs, fifth edition. 
USA: Lippincott Williams&Wilkins, 2002. ISBN 0-7817-2321-3. 
 
Macari S, Duffles LF, Queiroz-Junio CM. Oestrogen regulates bone resorption and 
cytokine production in the maxillae of female mice. Arch Oral Biol. 2015; 60(2): 333-
341. 
 
Malakova J, Brozmanova H, Vorisek V, et al. A Capillary GC Method Using Nitrogen 
Phosphorus Detection for Determination of Topiramate in Patients with Epilepsy.  
Chromatographia. 2007; 66 (5/6): 363-367. 
 
Malik P, Gasser RW, Moncayo RC, et al. Bone mineral density and bone metabolism 
in patients with major depressive disorder without somatic comorbidities. Progress in 
Neuro-Psychopharmacology and Biological Psychiatry. 2013; 44: 58-63. 
 
Marcus R, Feldman D, Kelsey J. Osteoporosis. United Kingdom: Academic press., 
1995. ISBN 0-12-470860-9. 
 
Maxhimer JB, Bradley JP, Lee JC. Signaling pathways in osteogenesis and 
osteoclastogenesis: Lessons from cranial sutures and applications to regenerative 





McCormick RK. Osteoporosis: Integrating Biomarkers and Other Diagnostic 
Correlates into the Management of Bone Fragility. Altern Med Rev. 2007; 12(2): 113-
45. 
 
Merideth CH. A single-center, double-blind, placebo-controlled evaluation of 
lamotrigine in the treatment of obesity in adults. J Clin Psychiatry. 2006 
Feb;67(2):258-62. 
 
Michelhaugh SK, Basha M, Rhoney DH, et al. Acute or chronic use 
of lacosamide does not alter its distribution between serum and cerebrospinal fluid. 
Epilepsia. 2015. doi: 10.1111/epi.13111. epub 
Moro-Alvarez MJ, Díaz Curiel M, de la Piedra C, et al. Bone disease induced by 
phenytoin therapy: clinical and experimental study. Eur Neurol. 2009;  62(4): 219-
230. 
 
Nagy V, Penninger JM. The RANKL-RANK Story. Gerontology. 2015; DOI: 
10.1159/000371845 Epub.  
 
Nissen-Meyer LS, Svalheim S, Taubøll E, et al. Levetiracetam, phenytoin, and 
valproate act differently on rat bone mass, structure, and metabolism. Epilepsia. 
2007; 48(10):1850-1860.  
 
Ohta T, Wergedal JE, Matsuyama T, et al. Phenytoin and fluoride act in concert to 
stimulate bone formation and to increase bone volume in adult male rats. Calcif 





Onodera K, Takahashi A, Mayanagi H, et al. Phenytoin-Induced Bone Loss and Its 
Prevention with Alfacalcidol or Calcitriol in Growing Rats.Calcif Tissue Int. 2001 69: 
109-116. 
 
Pack A. Bone health in people with epilepsy: is it impaired and what are the risk 
factors? Seizure. 2008; 17(2): 181-186.  
 
Pack AM, Morrell MJ, Randall A, et al. Bone health in young women with epilepsy 
after one year of antiepileptic drug monotherapy. Neurology. 2008; 70(18): 1586-
1593.  
 
Pack AM: Treatment of epilepsy to optimize bone health. Curr Treat Options Neurol. 
2011; 13(4): 346-354. 
 
Pack AM, Morrell MJ, McMahon DJ, et al.  Normal vitamin D and low free estradiol 
levels in women on enzyme-inducing antiepileptic drugs. Epilepsy Behav. 2011; 
21(4): 453-458. 
 
Perucca E. The Clinical Pharmacokinetics of the New Antiepileptic Drugs. Epilepsia. 
1999; 40 (9): 7-13. 
 
Phabphal K, Geater A, Limapichat K et al. The association between CYP 2C9 






Rabenda V, Nicolet D, Beaudart C, et al. Relationship between use of 
antidepressants and risk of fractures: a meta-analysis. Osteoporos Int. 2013; 24: 
121–137. 
 
Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J 
Biol Chem. 2010; 285(33): 25103-25108. 
 
Raisz LG. Physiology and Pathophysiology of Bone Remodeling. Clinical 
Chemistry.1999; 45(8): 1353-1358. 
 
Rattya J, Pakarinen AJ, Knip M. Early hormonal changes during valproate or 
carbamazepine treatment: a 3-month study. Neurology. 2001; 57(3): 440-444.   
 
Reimers A. New antiepileptic drugs and women. Seizure. 2014; 23 (8): 585 – 591. 
 
Richard D, Picard F,  Lemieux C, et al. The effects of topiramate and sex hormones 
on energy balance of male and female rats. Int J Obes Relat Metab Disord. 2002; 26 
(3): 344-353. 
 
Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake 
inhibitors on the risk of fracture. Arch Intern Med. 2007; 167: 188–194. 
 




osteoporosis. Bone. 2012; 51(3): 606-13. 
 
Roggia C, Gao Y, Cenci S, et al. Up-regulation of TNF-producing T cells in the bone 
marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. 
Proc Natl Acad Sci U S A. 2001; 98 (24): 13960 – 13965. 
 
Ryu SJ, Ryu DS, Kim JY, et al. Bone Mineral Density Changes 
after Orchiectomy using a Scrotal Approach in Rats. Korean J Spine. 2015; 12(2): 55-
59. 
 
Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover 
with valproate therapy in adults with epilepsy. Neurology. 2001; 57(3): 445-449.  
 
Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: 
paracrine regulators of bone metabolism and vascular function. Arterioscler. Thromb. 
Vasc. Biol. 2002; 22 (4):  549–553.  
 
Schürer C, Wallaschofski H, Nauck M, et al. Fracture Risk and Risk Factors for 
Osteoporosis: Results From Two Representative Population-Based Studies in North 
East Germany (Study of Health in Pomerania: SHIP-2 and SHIP-Trend). Dtsch 
Arztebl Int. 2015; 112(21-22): 365-71. 
 
Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. 





Shah AD, Shoback D, Lewiecki EM. Sclerostin inhibition: a novel therapeutic 
approach in the treatment of osteoporosis. Int J Womens Health. 2015; 7: 565-80.  
 
Shea ML, Garfield LD, Teitelbaum S, et al. Serotonin-norepinephrine reuptake 
inhibitor therapy in late-life depression is associated with increased marker of bone 
resorption. Osteoporosis Int. 2013; 24: 1741 – 1749.  
 
Sheth RD, Hermann BP. Bone mineral density with lamotrigine monotherapy for 
epilepsy. Pediatr Neurol. 2007; 37(4): 250-254. 
 
Svalheim S, Tauboll E, Surdova K, et al. Long-term levetiracetam treatment affects 
reproductive endocrine function in female Wistar rats. Seizure. 2008; 17: 203-209. 
 
Shea ML, Garfield LD, Teitelbaum S, et al. Serotonin-norepinefrine reuptsake 
inhibitor therapy in late-life depression is associated with increased marker of bone 
resorption. Osteoporos Int. 2013; 24(5): 1741-1749. 
 
Svalheim S, Røste LS, Nakken KO, et al. Bone health in adults with epilepsy. Acta 
Neurol Scand Suppl. 2011; 191: 89-95. 
 
Valimaki MJ, Tiihonen M, Laitinen K. Bone mineral density measured by dual-energy 
x-ray absorptiometry and novel markers of bone formation and resorption in patients 
on antiepileptic drugs. J Bone Miner Res. 1997; 9(5): 631-637.   
 




orchidectomized male rat model that 17beta-estradiol is a more effective bone-
sparing and anabolic agent than 5alpha-dihydrotestosterone. J Bone Miner Res. 
2002; 17(11): 2080-2086. 
 
Vanderschueren D, Vandenput L, Boonen S, et al. An aged rat model of partial 
androgen deficiency: prevention of both loss of bone and lean body mass by low-
dose androgen replacement. Endocrinology. 2000; 141: 1642–1647. 
 
Vanpee D, Laloyaux P, Gillet JB. Seizure and hyponatraemia after overdose of 
trazodone. The American Journal of Emergency Medicine. 1999; 17 (4): 430–431. 
 
Vega D, Maalouf NM, Sakhaee K. Increased propensity for calcium phosphate kidney 
stones with topiramate use. Expert Opin Drug Saf. 2007; 6: 547-57. 
 
Verrotti A, Greco R, Latini G, et al. Increased bone turnover in prepubertal, pubertal, 
and postpubertal patients receiving carbamazepine. Epilepsia. 2002; 43(12): 1488-
1492.  
 
Verrotti A, Agostinelli S, Coppola G, et al. A 12-month longitudinal study of calcium 
metabolism and bone turnover during valproate monotherapy. Eur J Neurol. 2010; 
17(2): 232-237. 
 
Walker MC and Sander JW. New anti-epileptic drugs. Expert Opin Investig Drugs. 





Walsh MC, Choi Y. Biology of the RANKL–RANK–OPG system in immunity, bone, 
and beyond. Front Immunol. 2014; 20(5): 511. 
 
Warden JS, Nelson IR, Fuchs RK, et al. Serotonin (5-
hydroxytryptamine) transporter inhibition causes bone loss in adult mice 
independently of estrogen deficiency. Menopause. 2008; 15 (6): 1176-1183.  
 
Warden JS, Roblingb AG, Haneyc EM, et al. The emerging role of serotonin (5-
hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-
density lipoprotein receptor-related protein 5 (LRP5). Bone. 2010; 46(1): 4 – 12. 
 
Wheater G, Elshahaly M, Tuck SP, et al. The clinical utility of bone marker 
measurements in osteoporosis. J Transl Med. 2013; 29 (11): 201. 
Weilbaecher KN, Guise TA,  McCauley LK. Cancer to bone: a fatal attraction. Nature 
Reviews Cancer. 2011; 11: 411-425. 
 
Wu Q, Bencaz AF, Hentz JG, et al. Selective serotonin reuptake 
inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control 
studies. Osteoporos Int. 2012;23(1):365-75.  
 
Wu Q, Qu W, Crowell MD, et al. Tricyclic antidepressant use and risk of fractures: a 





Zhang J, Wang KX, Wei Y, et al. Effect of topiramate and carbamazepine on bone 
metabolism in children with epilepsy.  Zhongguo Dang Dai Er Ke Za Zhj. 2010; 12(2): 
96-98. 
 
Zhang L, Xie WW, Li LH, et al. Efficacy and safety of prolonged-
release trazodone in major depressive disorder: a multicenter, randomized, double-
blind, flexible-dose trial. Pharmacology. 2014; 94: 199–206. 
 
Zhaoxia LI, Zhuanglei GAO, Chengjuan JIN, et al. The Efficacy of Leviteracetam 










































































































































11.5. Appendix 5  
 
 
144 
 
 
 
 
 
145 
 
 
146 
 
 
147 
 
 
 
 
